Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
Confidential/Proprietary Information  
Page 1 of 84 Clinical Study Protocol 
Protocol Title: 
A parallel-group, Phase I/II , randomized, modified double-blind, 3-arm, active comparator, mul ti-
center , prevention study to evaluate the immunogenicity and safety of tw o adjuvante d dose levels 
of Panblok H7+MF 59 influenza vacc ine compar ed with an unadjuvante d dose of Panblok H7 in 
participants 18 years of age and older 
Study Code: VAM00001 
NCT number: 
[STUDY_ID_REMOVED] 
Amendment Number: not applicable  
Compound: Panblok + MF59 
Brief Title: 
Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity 
and Safety with an Unadjuvanted 
Dose of Panblok H7 in Participants 18 Years of Age and Older 
Study Phase: I/II 
Sponsor Name and Legal Registered Address: 
Sanofi Pasteur Inc. 
Discovery Drive, Swiftwater, PA 18370-0187, USA 
Manufacturer: Same as Sponsor 
Regulatory Agency Identifier Numbers: 
WHO UTN: U1111 -1256 -9115  
US IND Number: 28567  
Protocol Version Number: 2.0 
Approval Date: 14 September 2022  
Responsible medical officer ( RMO) , and designee(s),  and pharmacovigilance (PV) representative 
names and contact information will be provided separately.  
The study centers, the investigators at each center, and the Coordinating Investigator  are also 
listed in a separate document.  

Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 2 of 84 Document History   
 
Previous Version  Date  Comments  
1.0 19 May 2022  Version submitted to the US Food and Drug Administration 
and the Inst itutional Review Board (Advarra)  
Overall Rationale for the Protocol Update:  
The main reason for updating protocol version 1.0 to protocol version 2.0 was to address feedback 
from the US Food and Drug Administration. The feedback included a request to ad d the collection 
of medically attended adverse events throughout the study and to clarify that the electronic diary 
will be used by the study participant to record safety data.  
 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 3 of 84 Table  of Contents  
Document History  ................................ ................................ ................................ ............................  2 
List of Tables  ................................ ................................ ................................ ................................ .... 7 
List of Figures  ................................ ................................ ................................ ................................ .. 8 
1.1 Schema  ................................ ................................ ................................ ............................  14 
1.2 Schedule of Activities (SoA)  ................................ ................................ ..........................  15 
2 Introduction  ................................ ................................ ................................ .....................  17 
2.1 Study Rationale  ................................ ................................ ................................ ...............  17 
2.2 Background  ................................ ................................ ................................ .....................  17 
2.3 Benefit/Risk Assessment  ................................ ................................ ................................  21 
2.3.1  Risks from Study Participation  ................................ ................................ .....................  21 
2.3.2  Benefits from Study Participation  ................................ ................................ ................  23 
2.3.3  Overall Benefit -Risk Conclusion  ................................ ................................ ..................  24 
3 Objectives and Endpoints  ................................ ................................ ...............................  25 
4 Study Design  ................................ ................................ ................................ ....................  27 
4.1 Overall Design  ................................ ................................ ................................ ................  27 
4.2 Scient ific Rationale for Study Design  ................................ ................................ .............  28 
4.3 Justification for Dose  ................................ ................................ ................................ ...... 28 
4.4 End of Study Definition  ................................ ................................ ................................ .. 28 
5 Study Population  ................................ ................................ ................................ .............  29 
5.1 Inclus ion Criteria  ................................ ................................ ................................ ............  29 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...........  30 
5.3 Lifestyle Considerations  ................................ ................................ ................................ . 31 
5.4 Screen Failures  ................................ ................................ ................................ ................  31 
5.5 Criteria for Temporarily Delaying Enrollment, Randomization, Administration of 
Study Intervention, or Blood Samplings  ................................ ................................ .........  31 
6 Study Inte rventions and Concomitant Therapy  ................................ ...........................  32 
6.1 Study Interventions Administered  ................................ ................................ ..................  32 
6.2 Preparation, Handling, Storage, and Accountability  ................................ ......................  33 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 4 of 84 6.3 Measures to Minimize Bias: Randomization and Blinding  ................................ ............  34 
6.3.1  Randomization and Allocation Procedures  ................................ ................................ .. 34 
6.3.2  Blinding and Code -breaking Procedures  ................................ ................................ ...... 35 
6.4 Study Intervention Compliance  ................................ ................................ ......................  36 
6.5 Dose Modification  ................................ ................................ ................................ ..........  36 
6.6 Continued Access to Study Intervention After the End of the Study  .............................  36 
6.7 Treatment of Overdose ................................ ................................ ................................ .... 36 
6.8 Concomitant Therapy  ................................ ................................ ................................ ...... 37 
6.8.1  Rescue Medicine  ................................ ................................ ................................ ...........  38 
7 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  ................................ ................................ ..........................  38 
7.1 Discontinuation of Study Intervention  ................................ ................................ ............  38 
7.1.1  Temporary Contraindications  ................................ ................................ .......................  38 
7.1.2  Definitive Contraindications  ................................ ................................ .........................  38 
7.1.3  Other Reasons  ................................ ................................ ................................ ...............  39 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ................  39 
7.3 Lost to Follow -up ................................ ................................ ................................ ............  40 
8 Study Assessments and Procedures  ................................ ................................ ...............  40 
8.1 Efficacy and Immunogenicity Assessments  ................................ ................................ ... 41 
8.1.1  Efficacy Assessments  ................................ ................................ ................................ ... 41 
8.1.2  Immunogenicity Assessments  ................................ ................................ ......................  41 
8.2 Safety Assessments  ................................ ................................ ................................ .........  42 
8.2.1  Medi cal History  ................................ ................................ ................................ ............  42 
8.2.2  Physical Examinations  ................................ ................................ ................................ .. 42 
8.2.3  Vital Signs  ................................ ................................ ................................ ....................  42 
8.2.4  Clinical Safety Laboratory Tests  ................................ ................................ ..................  42 
8.2.5  Pregnancy Testing  ................................ ................................ ................................ ........  43 
8.3 Adverse Events (AEs), Serious Adverse Events, and Other Safety Reporting ...............  43 
8.3.1  Time Period and Frequency for Collecting AE and SAE Information  .........................  43 
8.3.2  Method of Detecting AEs and SAEs  ................................ ................................ ............  44 
8.3.3  Follow -up of AEs and SAEs  ................................ ................................ ........................  44 
8.3.4  Regulatory Reporting Requirements for SAEs  ................................ ............................  45 
8.3.5  Pregnancy  ................................ ................................ ................................ .....................  45 
8.3.6  Adverse Events of Special Interest  ................................ ................................ ...............  46 
8.3.7  Medically Attended Adverse Events  ................................ ................................ ............  46 
8.4 Pharmacokinetics  ................................ ................................ ................................ ............  46 
8.5 Genetics  ................................ ................................ ................................ ...........................  46 
8.6 Biomarkers  ................................ ................................ ................................ ......................  46 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 5 of 84 8.7 Immunogenicity Assessments  ................................ ................................ .........................  46 
8.8 Medical Resource Utilization and Health Economics  ................................ ....................  46 
8.9 Leftover Biological Samples and Use of Data  ................................ ................................  47 
9 Statistical Considerations  ................................ ................................ ...............................  48 
9.1 Statistical Hypotheses  ................................ ................................ ................................ ..... 48 
9.2 Sample Size Determination Based on HAI Data  ................................ ............................  48 
9.3 Analysis Sets  ................................ ................................ ................................ ...................  49 
9.4 Statistical Analyses  ................................ ................................ ................................ .........  50 
9.4.1  General Considerations  ................................ ................................ ................................ . 50 
9.4.2  Primary Endpoints  ................................ ................................ ................................ ........  51 
9.4.3  Secondary Endpoints  ................................ ................................ ................................ .... 52 
9.4.4  Other Analysis  ................................ ................................ ................................ ..............  54 
9.5 Interim Analyses  ................................ ................................ ................................ .............  54 
10 Supporting Documentation and Operational Considerations  ................................ .... 55 
10.1 Appendix: Regulatory, Ethical, and Study Oversight Considerations  ............................  55 
10.1.1  Regulatory and Ethical Considerations  ................................ ................................ ........  55 
10.1.2  Financial Disclosure  ................................ ................................ ................................ ..... 56 
10.1.3  Informed Consent Process  ................................ ................................ ............................  56 
10.1.4  Data Protection  ................................ ................................ ................................ .............  57 
10.1.5  Committees Struct ure ................................ ................................ ................................ ... 59 
10.1.6  Dissemination of Clinical Study Data  ................................ ................................ ..........  60 
10.1.7  Data Quality Assurance  ................................ ................................ ................................  60 
10.1.8  Source Documents  ................................ ................................ ................................ ........  61 
10.1.9  Study and Site Start and Closure  ................................ ................................ ..................  62 
10.1.10  Publication Policy  ................................ ................................ ................................ .........  62 
10.2 Appendix: Clinical Laboratory Tests  ................................ ................................ ..............  63 
10.3 Appendix: AEs and SAEs: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting  ................................ ................................ ...............................  64 
10.3.1  Definition of AE  ................................ ................................ ................................ ...........  64 
10.3.2  Definition of S AE ................................ ................................ ................................ .........  66 
10.3.3  Recording and Follow -Up of AE and/or SAE  ................................ ..............................  68 
10.3.4  Reporting of SAEs  ................................ ................................ ................................ ........  70 
10.3.5  Assessment of Intensity  ................................ ................................ ................................  71 
10.3.5.1  Tables for Clinical Abnormalities  ................................ ................................ ..............  71 
10.3.5.1.1  Solicited AR Intensity Grading Scale  ................................ ................................ ...... 71 
10.3.5.1.2  Serious and Non -serious Unsolicited AE Intensity Grading Scale  ..........................  75 
10.4 Appendix: Contraceptive and Barrier Guidance  ................................ .............................  76 
10.4.1  Definitions  ................................ ................................ ................................ ....................  76 
10.4.2  Contraception Guidance  ................................ ................................ ...............................  77 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 6 of 84 10.5 Appendix: Contingency measures for a regional or national emergency that is 
declared by a governmenta l agency  ................................ ................................ ................  78 
10.6 Appendix: Risk -based Approach  ................................ ................................ ....................  78 
10.7 Appendix: Abbreviations  ................................ ................................ ................................  79 
11 References  ................................ ................................ ................................ ........................  82 
12 Sponsor Sig nature Page  ................................ ................................ ................................ .. 84 
 
  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 7 of 84  
List of Tables   
Table 2.1 - Schedule of activities  ................................ ................................ ................................ .. 15 
Table  2.1 - Identified and Potential risks of clinical signi ficance and risk management  ..............  21 
Table  3.1 - Objectives and endpoints  ................................ ................................ ............................  25 
Table 4.1 – Overall design  ................................ ................................ ................................ .............  27 
Table 6.1 - Study interventions Administered  ................................ ................................ ...............  32 
Table 9.1 - Descriptive statistics produced  ................................ ................................ ....................  48 
Table 9.2 - Probability calculation  ................................ ................................ ................................  49 
Table 10.1 - Protocol -required  safety laboratory tests  ................................ ................................ .. 63 
Table 10.2 - Solicited injection site reactions: terminology, definitions, and intensity scales 
– Adul ts 18 years of age and older  ................................ ................................ ................................  72 
Table 10.3 - Solicited systemic reactions: terminology, definitions, and intensity scales – 
Adults  18 years of age and older  ................................ ................................ ................................ ... 74 
 
  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 8 of 84 List of Figures   
Figure 1 - Graphical study design  ................................ ................................ ................................ . 14 
 
 
  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 9 of 84 Protocol Title:  
A parallel -group, Phase I/II, randomized, modified double -blind, 3 -arm, active comparator, multi -
center, prevention  study to evaluate the immunogenicity and safety  of two adjuvanted  dose levels  
of Panblok H7+MF59 influenza  vaccine compared with an unadjuvanted dose of  Panblok H7 in 
participants 18 years of age and older  
Brief Title:  
Study on Two Adjuvanted Dose  Levels of Panblok H7+MF59 Compared for Immunogenicity and 
Safety  with an Unadjuvanted Dose of  Panblok H7 in Partic ipants 18 Years of Age and Older  
Rationale:  
VAM00001 will be a Phase I/II, randomized, modified double -blind, multi -center, prevention 
study to be conducted in approximately 700 adult participants (350 adults 18  - 64 years of age and 
350 adults ≥  65 years of age). The aim of this study is to assess the immunogenicity and safety of 
2 dose levels of Panblok H7+MF59 (7.5 µg and 15 μg of recombinant hemagglutinin [rHA]) 
compared with an unadjuvanted dose of Panblok H7 (45 μg of rHA) in order to select one dose 
formulation for further clinical development. An active unadjuvanted comparator was chosen to 
potentially assess an antigen -sparing effect of the MF59 adjuvant. Participants will be randomized 
in a 3:3:1 ratio and the vaccination schedule for all participa nts will consist of 2  doses, 
administered 21  days apart.  
 
Objectives and Endpoints  
Objectives  Endpoints  
Primary   
Immunogenicity  
To assess the antibody response induced 
by each study dose group of Panblok  
H7+MF59 vaccine (7.5 µg and 15  µg) 
compared with unadjuvanted Panblok H7 
(45 µg) by hemagglutination inhibition 
using horse red blood cells (HIH) and 
seroneutralization (SN) measurement 
methods at day (D) 22 and D43 (ie, 
21 days after each vaccination) in  
participants 18  - 64 years and ≥  65 years 
of age  Immunogenicity  
The following immunogenicity endpoints will be 
summarized:  
Immunogenicity by HIH measurement method:  
• Hemagglutination inhibition (HAI) antibody (Ab) titers 
obtained on D22 and D43 for compari son with D01, 
D202, and D387  
• Individual HAI Ab titers ratio D22/D01 and D43/D01; 
and D202/D01 and D387/D01  
• Seroconversion defined as titer < 10 (1/dilution [1/dil]) 
on D01 and post -injection titer ≥ 40 (1/dil) on D22 or 
D43; or defined as titer ≥  10 (1/dil ) on D01 and a ≥  4-
fold increase in titer (1/dil) on D22 or D43  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 10 of 84 • Individual HAI Ab titers ≥ 40 (1/dil) on D22 and D43; 
and D01, D202, and D387  
• Detectable HAI Ab titer, ie, with a titer ≥ 10 (1/dil) on 
D01, D22, D43, D202, and D387  
Immunogenicity by SN measu rement method:  
• Neutralization (NT) Ab titer obtained on D22 and D43 
for comparison with D01, D202, and D387  
• Individual NT Ab titers ratio D22/D01, D43/D01, 
D202/D01, and D387/D01  
• NT Ab titers ≥ 20 (1/dil), ≥ 40 (1/dil), ≥  80 (1/dil) on 
D22 and D43; compare d to D01, D202, and D387  
• Fold increase in NT Ab titer [post/pre] ≥  2 and ≥  4 on 
D22 and D43  
• Detectable NT Ab titer, ie, with a titer ≥ 10 (1/dil) on 
D01, D22, D43, D202, and D387  
Secondary   
Safety  
To assess the safety profile in each study 
vaccine group  in participants 
18 - 64 years and ≥  65 years of age 
throughout the study  Safety  
The following safety endpoints will be summarized:  
• Presence of any unsolicited systemic adverse events 
(AEs) reported in the 30  minutes after each vaccination  
• Presence of solicited (prelisted in the participant’s 
electronic diary [eDiary] and case report book [CRB]) 
injection site reactions and systemic reactions occurring 
up to 7 days after each  / any vaccination  
• Presence of unsolicited AEs up to 21 days after 
each / any v accination  
• Presence of medically attended adverse events 
(MAAEs) throughout the study  
• Presence of adverse events of special interest (AESIs) 
throughout the study  
• Presence of serious adverse events (SAEs) (including 
AESIs) throughout the study  
Overall Desi gn 
 
Type of design  parallel, multi -center  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 11 of 84 Phase  I / II 
Control method  active comparator  
(comparator = Panblok H7 (45 µg) unadjuvanted)  
Study population  healthy adults 18 years of age and older  
Countries  United States  
Level and method of blinding  modified double -blind  
Study intervention assignment method  randomization  
 
Brief Summary:  
The purpose of this study is to compare 2 dose levels of Panblok H7 (7.5 µg and 15 μg of rHA) 
with a standard 9.75 mg squalene dose of adjuvant MF59  to Panblok H7 ( 45 µg) unadjuvanted in 
approximately 700  adult participants in order to select one dose formulation to be used for further 
clinical development. The randomization ratio will be 3:3:1 for Panblok H7 ( 7.5 µg) + MF59, 
Panblok H7 (1 5 µg) + MF59, and Panblok H7 (45 µg) unadjuvanted , respectively. Each study 
group will be stratified into the age groups 18 -64 years (350 participants) and ≥ 65 years of age 
(350 participants).  
 
Study details include:  
Treatment Duration:  Eligible study participants will be randomized to receive 2 doses by 
intramuscular (IM) route, 21 days apart, of either Panblok H7 ( 7.5 µg) + MF59, Panblok H7 
(15 µg) + MF59, or  Panblok H7 ( 45 µg) unadjuvanted. A pre -vaccination (baseline) blood sample 
will be taken during Visit (V) 01 (D01) and post -vaccination blood samples will be taken during 
V02, V03, V04, and V05 (ie, D22, D43, D202, and D387) for HIH and SN testing in order to 
assess the immune response after Dose 1 and Dose 2 of the study intervent ion and to assess the 
persistence of the immune response at 6 and 12 months after the last vaccination.  
Visit Frequency : a total of 5 visits. Visit 2 and Visit 3 will occur 22 days and 43 days, 
respectively, after Visit 1. There will be 2 follow -up visits,  at 6 months and 12 months after the 
last vaccination (ie, after Visit 2).  
 
Number of Participant s: 
A total of 700  participants is expected to be randomized with the aim to obtain a total 
of 630 evaluable participants.  
 Group 1:  
Panblok H7 (7.5 µg) + MF59  Group 2:  
Panblok H7 (15 µg) + MF59  Group 3:  
Panblok H7 (45 µg) 
unadjuvanted  Total  
 18 - 64 years  ≥ 65 years  18 - 64 years  ≥ 65 years  18 - 64 years  ≥ 65 years  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 12 of 84 Planned 
number of 
Participants  150 150 150 150 50 50 700 
 
Intervention Groups and Duration:  
In each age group (18  - 64 years of age and ≥  65 years of age), eligible participants will be 
randomized in a 3:3:1 ratio to receive 2 doses, 21 days apart (ie, D01 and D22), by IM route of 
either Panblok H7+MF59 at 7.5  µg, Panblok H7+MF59 at 15  µg, or unadj uvanted Panblok H7 at 
45 µg. 
The study  duration for each participant will be approximately 13 months.  
 
Study interventions  
Two of the three  Investigational Medicinal Products (IMPs) include the MF59 adjuvant which is 
an oil -in-water emulsion composed of squalene and stabilized by the addition of 2  emulsifiers, 
polysorbate 80 and sorbitan trioleate, and a low ionic -strength buffer.  
Each of the  3 IMPs contains thimerosal.  
The composition of the 3 IMPs to be used in this study is described below:  
Panblok  H7 (7.5 µg) + MF59:  
Monovalent Recombinant H7  influenza vaccine [A/Guangdong/17SF003/2016 (H7N9)] with 
MF59  
• Form: Suspension  
• Composition: 0.5  mL dose, 7.5  µg rHA with 9.75  mg squalene of MF59 adjuvant, and 
0.01%  thimerosal presented in vials  
• Route: IM  
Panblok  H7 (15 µg) + MF59:  
Monovalent Recombinant H7  influenza vaccine [A/Guangdong/17SF003/2016 (H7N9)] with 
MF59  
• Form: Suspension  
• Composition: 0.5  mL dose, 15  µg rHA with 9.75  mg squalene of MF59 adjuvant, and 
0.01%  thimerosal presented in vials  
• Route: IM  
Panblok  H7 (45 µg) unadjuvanted  
Monovalent Recombinant H7  influenza vaccine [A/Guangdong/17SF003/2016 (H7N9)]  
• Form: Liquid  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 13 of 84 • Composition: 0.5  mL dos e, 45  µg rHA, and 0.01%  thimerosal presented in vials  
• Route: IM  
 
Statistical considerations:  
The statistical analysis will be conducted as follows:  
• The study will be unblinded after all immunogenicity and safety data are collected for the 
follow -up period of 3 weeks after D22 (ie, 21 days after the last vaccination).  
• The final database lock will occur after the 12 -month follow -up. 
No adjustment for multiplicity is planned in this study.  
Details will be provided in the Statistical Analysis Plan (SAP).  
Primar y endpoint (Immunogenicity by HIH and SN measurement methods):  
The immunogenicity parameters will be calculated with their 95% confidence intervals (CIs) 
using the exact binomial distribution (Clopper -Pearson method) for proportions and using normal 
approx imation of log -transformed for geometric mean titers (GMTs) and GMTs ratio. The 
95% CI of proportions difference (ie, difference in seroconversion) will be calculated using 
Wilson Score method without continuity correction. All analyses will be conducted b y dose group 
and by age stratum.  
• GMTs of HAI Ab titers and NT Ab titers obtained on D22 and D43 for comparison with D01, 
D202, and D387.  
• Geometric mean of individual ratios of HAI Ab titers and NT Ab titers of D22/D01 and 
D43/D01; and D202/D01, and D387/D01.  
• Percent of participants with seroconversion defined as HAI Ab titer < 10 (1/dil) on D01 (pre -
vaccination) and post -vaccination titer ≥  40 (1/dil) on D22 or D43; or HAI Ab titer ≥ 10 (1/dil) 
on D01 and a ≥  4-fold increase in titer (1/dil) on D22 o r D43.  
• Percent of participants with fold increase in NT Ab titer [post -vaccination/pre -vaccination] ≥  2 
and ≥  4 on D22 and D43; and D202, and D387.  
• Percent of participants with HAI Ab titers ≥ 40 (1/dil), and percent of participants with NT Ab 
titers ≥ 40 (1/dil) on D22 and D43; and D202 and D387.  
• Reverse cumulative distribution curves (RCDCs) of pre -vaccination titer prior to the first 
vaccination at D01 and post -vaccination titer at D22, D43, D202, and D387 will be generated 
for each dose.  
Secondary endpo ints (Safety):  
For the main safety parameters, 95% CIs of point estimates will be calculated using exact 
binomial method (Clopper -Pearson method) for single proportions and using the normal 
approximation for quantitative data.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 14 of 84 Analysis will be conducted fo r each dose group, by strata of age, and by the period of 7 days and / 
or the period of 21 days after each vaccination, and / or by interval of visits (ie, between Visit 4 
[6-month follow -up] and Visit 5 [12 -month follow -up]) for safety data collected from  D01 to the 
end of the study.  
All analyses will be descriptive, and no hypotheses will be tested.  
The number of participants with documented safety will be used as denominator of the 
frequencies.  
Data Monitoring/Other Committee:  
No 
1.1 Schema   
The graphical design of VAM00001 study is presented in Figure 1  
Figure 1 - Graphical study design   
 
 
 
BL: Blood sample  
VAC: vaccination  
 

Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 15 of 84 1.2 Schedule of Activities (SoA)   
Table 2.1 - Schedule of activities   
Phase I/II Study,  5 Visits, 2 Vaccinations, 5  Blood Samples, 13  Months’ Duration Per 
Participant  
Visit/Contact  Collection 
of 
information 
in the CRF  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  
Study timelines (days)   D01 21 days 
post V01  
(D22)  21 days 
post V02  
(D43)  6 months 
post V02  
(D202)  12 months 
post V02  
(D387)  
Time windows (days)    [+7 D] [+7 D] [+14  D] [+14  D] 
Visit procedures:        
Informed consent  X X     
Inclusion/exclusion criteria  X X     
Collection of demographic 
data X X     
Urine pregnancy test (if 
applicable)   X X    
Collection of Medical 
history  X 
Significant 
Medical 
History * X     
Physical examination   X X    
Temporary and definitive 
contraindications  X  X    
Pre-vaccination temperature   X X    
Randomization  X X     
Allocation of participant  
number  X X     
Dose assignment by IRT   X X    
Blood sampling (BL)  
[40 mL/visit]  X BL0001  
Pre-vac BL0002  
Pre-vac BL0003  BL0004  BL0005  
Vaccination (vac)  X X X    
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 16 of 84 Visit/Contact  Collection 
of 
information 
in the CRF  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  
eDiary provided †  X     
eDiary reviewed ‡   X X X X 
Collection of solicited 
injection site and systemic 
reactions  X X X X   
Collection of unsolicited 
adverse events (AEs)  X X X X   
Collection of concomitant 
medications  X 
Reportable 
concomitant 
medication  X X X   
Collection of medically 
attended AEs (MAAEs)  X To be reported at any time during the study  
Collection of serious 
adverse events (SAEs), 
including AESIs  X To be reported at any time during the study  
Collection of pregnancies  X To be reported at any time during the study  
End of Study Intervention 
Phase § X   X   
End of study**  X     X 
AESI: adverse event of special interest; CRF: case report form; D: day; DC: diary card; IRT: interactive response 
technology; V: visit  
* Significant medical history is described in Section  8.2.1  of the protocol  
† Electronic diary application should be downloaded to the participant’s electronic device (such as mobile phone or 
tablet).  
‡ Electronic diary is the primary method for safety data collection. However, paper diary cards will also be available 
for use as a back -up solution in case of major bre akdown of the app or as determined by the Sponsor’s study clinical 
team.  
§ In case of participant discontinuation at a visit, the entire visit will be completed.  
** All participants will be scheduled to attend V05 for blood sampling and safety follow -up. H owever, if any 
participants discontinue the study early, they are still to be followed for safety and are to be contacted by phone to 
identify the occurrence of any MAAEs, SAEs, and AESIs that had not yet been reported. The site should attempt to 
contact t hem and complete the 12 -month safety follow -up (and all other scheduled safety follow -ups), except if they 
specified that they do not want to be contacted again and it is documented in the source document.  
 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 17 of 84 2 Introduction   
2.1 Study Rationale   
VAM00001 will be a Phase I/II, randomized, modified double -blind, multi -center, prevention  
study to be conducted in approximately 700  adult participants (350 adults 18  – 64 years of age and 
350 adults ≥  65 years of age). The aim of this study is to assess the immunogenicity and safety  of 
2 dose levels of Panblok H7+MF59 (7.5  µg and 15  μg of rHA) compared with an  unadjuvanted 
dose of Panblok H7 (45  μg of rHA) in order to select one dose formulation for further clinical 
development. An active unadjuvanted comparator was chosen to potentially assess an antigen -
sparing effect of the MF59 adju vant. Participants will be randomized in a 3:3:1 ratio and the 
vaccination schedule for all participants  will consist of 2  doses, administered 21  days apart.  
2.2 Background   
Influenza  is a contagious, acute viral respiratory disease caused by influenza type  A and type  B 
viruses. Genetic and antigenic variations are an important feature of the influenza virus with the 
viral hemagglutinin (HA) and neuraminidase (NA) antigens subject to c ontinuous, sequential 
evolution within immune or partially immune populations. Antigenic shift occurs when 
completely new viral subtypes emerge, typically through gene reassortment with other circulating 
strains and acquisition of antigenically different g ene sequences. These new influenza virus strains 
which arise from antigenic shift can cause influenza pandemics: global epidemics caused by an 
influenza virus that infects a large proportion of the human population because the new influenza 
virus strain ha s not circulated in humans previously or has not circulated for a long period of time 
rendering most of the human population with no immunologic memory for such a virus or limited 
memory in older adults who may have been exposed if the virus circulated pre viously. Influenza 
pandemics occur at irregular intervals with four influenza pandemics occurring over the past 
century: the Spanish flu in 1918 (H1N1), the Asian influenza in 1957 (H2N2), the Hong Kong 
influenza in 1968 (H3N2), and the swine flu in 2009 ( H1N1pdm) ( 1). 
Demonstrating the potential for a newly emerging pandemic strain of influenza to circulate 
globally within a matter of months, the most recent influenza pandemic, a novel H1N1 influenza 
A virus, emerged in North America in April 2009, and by June, the World Health Organization 
had declared a worldwide pandemic, reflecting community -level transmission of the novel H1N1 
pandemic str ain around the world. Estimates of influenza -related deaths worldwide during this 
pandemic ranged from 105,700 to 395,600 in one modeling study ( 2). However, the 2009 novel 
H1N1 disease generally did not appear to be more severe than seasonal influenza and adequate 
immunity was induced by a single dose of vaccine in individuals 10 years of age and older. This 
H1N1 strain has become a dominant ci rculating strain since the 2009 -2010 season and has been 
included in subsequent seasonal influenza formulations since the 2010 -2011 season.  
As vaccination remains the most effective means of preventing influenza infection and 
complications associated with the disease ( 3), preparation for the next influenza strain with 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 18 of 84 pandemic potential has become a high priority for all public health authorities, with a focus on 
avian influenza strains such as the H5N1 and H7N9 strains.  
Avian influenza is an infectious disease of birds caused by type A strains and occurs worldwide. 
Outbreaks of avian influenza have been caused by viruses of the H5, H6, H7, H9, and H10 
subtypes of influenza A, all capable of infecting and  causing disease in humans ( 4). Since 2013, 
the H7N9 avian influenza strain has been the cause of 6 annual “waves” of outbreaks among 
poultry  handlers in China ( 5). Of the 1567 cases since 2013, there have been 650 deaths (42% 
mortality) and while there has yet to be evidence of su stained human -to-human transmission, the 
strain does appear to pose a credible threat as a potential pandemic strain ( 5). Thus, pandemic 
preparedness efforts have recently been directed toward the production of a vaccine for this strain. 
To limit the impact of such an outbreak, the availability of a sufficient number of doses of a safe 
and effective vaccine in a short time frame is a high prior ity. Since most people are 
immunologically naïve to an avian pandemic influenza strain, the primary difficulty is that large 
amounts of antigen are needed to induce antibody titers that are expected to be protective ( 6). 
Approaches such as the use of adjuvants are needed in order to both improve the immunogenicity 
of pandemic influenza vaccines and to allo w for antigen -sparing in order to i ncrease production 
capacity.  
Sanofi Pasteur’s Panblok H7+MF59 is a new pre -formulated, recombinant, adjuvanted (MF59), 
dose-sparing vaccine that is being developed to provide an efficient and effective way to prevent 
pand emic influenza disease and to reduce the impact of pandemic influenza A (eg, H7N9) virus.  
Panblok H7 is a monovalent rHA from A/H7N9 influenza strain expressed in the 
baculovirus/insect cell system. The formulation will contain thimerosal and MF59 adjuvant  
premixed in vials for IM injection.  
The MF59 adjuvant is an oil -in-water emulsion adjuvant composed of squalene and has been used 
for years by Novartis/Seqirus in vaccines marketed in the US, Europe, and other countries ( 7). 
With approximately 30 years of clinical experience and more than 160  million doses of 
adjuvanted vaccines distributed, MF59 has an established safety profile and has been shown to be 
well tolerated in children and adults ( 8) (9). 
A detailed description of the chemistry, pharmacology, efficacy, and safety of Panblok H7 is 
provided in the Investigator’s Brochure (IB).  
 
Clinical Studies with Panblok  
Since 2010, four completed clinical studies have been conducted using different formulations of 
Panblok (at different rHA concentrations and with or without different adjuvants). A summary of 
3 clinical studies conducted by Protein Sciences Corporation (PSC) ( 10) (11) (12) and 1  clinical 
study conducted by the Biomedical Advanced Research and Development Authority (BARDA) 
(13) is presented below.  
Study PSC22  
PSC22 study was a Phase I/II randomized, prospective, modified double -blind, active -controlled, 
and placebo -controlled  study to assess the safety and immunogenicity of 2 doses of Panblok H5 at 
4 dose levels o f rHA (3.8, 7.5, 15, and 45  μg) adjuvanted with Glucopyranosyl Lipid A in stable 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 19 of 84 oil-in-water emulsion (GLA/SE) compared to unadjuvanted formulations (45 and 135  μg rHA ) 
and normal saline placebo to determine the optimal rHA dose level and to assess the added 
immunogenicity afforded by the addition of the GLA/SE adjuvant ( 10). 
The rHA in Panblok H5 was derived from A/Indonesia/5/05 (H5N1) infl uenza virus strain. 
Panblok H5 was diluted in normal saline to the concentration appropriate for the assigned dose 
level and administered either as rHA alone (ie, unadjuvanted) or formulated at the study sites with 
GLA/SE adjuvant prior to administration. Two injections, 21 days apart, were administered by IM 
route in 392 healthy adults 18 to <  50 years of age.  
Data from PSC22 study showed that adjuvanted and unadjuvanted Panblok H5 were well 
tolerated. Solicited injection site pain, injection site tenderne ss, muscle pain, and fatigue were 
more frequent in the adjuvanted Panblok H5 groups compared to unadjuvanted Panblok H5 and 
placebo groups after both doses. Unsolicited AEs from D0 to D42 were similar in frequency and 
relationship to vaccine across all gro ups. None of the SAEs reported during the study were 
considered to be related to study products.  
The percentage of subjects with post -vaccination HAI titers ≥  40 across all adjuvanted groups 
were 66%  to 81.5% compared to non -adjuvanted at 16.7%  to 31.5% an d placebo at 0%. However, 
the Food and Drug Administration  (FDA) criterion for licensure (lower bound of 2 -sided 95% CI 
for percentage of subjects achieving an HAI antibody titer ≥  1:40 should be ≥  70%) was not met 
for any of the groups in the clinical stu dy. 
Study PSC25  
PSC25 study was a Phase I/II randomized, observer -blind, multi -center study to assess the 
immunogenicity and safety of 2 doses of Panblok H5 at 3 dose levels of rHA (3.8, 7.5 and 15  μg) 
with a stable oil -in-water emulsion (SE) adjuvant comp ared to an unadjuvanted Panblok H5 
(7.5 μg rHA)  to select the optimal dose level of rHA to carry forward for future adjuvanted 
Panblok H5  vaccine de velopment (11). 
The rHA in Panblok H5 was derived from A/Indonesia/5/05 (H5N1) influenza virus strain. 
Panblok H5 was diluted in normal saline to the concentration appropriate for the assigned dose 
level and administered either as rHA alone (ie, unadjuvanted) or formulated at the study sites with 
SE adjuvant prior to administration. Two doses, 21 days apart, were administered by IM route in 
341 healthy adults 18 to <  50 years of age.  
Data from PSC25 study showed that adjuvanted and unadjuvanted Panblok H5 had an acceptable 
safety profile. Solicited local injection site pain and tenderness were more frequent in the 
adjuvanted Panblok H5 groups compared to unadjuvanted Panblok H5 group after both doses.  
Unsolicited AEs from D0 to D42 were similar in frequency and relationship to vaccine across all 
groups. The incidence of SAEs was <  1% overall, and none were considered to be related to study 
vaccines.  
All dose levels of SE -adjuvanted Panblok H5 met FDA r egulatory guidance for licensure criterion 
for seroconversion (ie, lower bound of the two -sided 95% CI should be ≥  40%) after 2 doses at 
D42. However, FDA criterion for post -immunization titer ≥  1:40 (ie, lower bound of the two -
sided 95% CI should be ≥  70%) was met by the adjuvanted 15  µg dose group only. No vaccine 
groups met any criteria for licensure after a single dose of vaccine.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 20 of 84 Study PSC26  
PSC26 study was a Phase I/II, randomized, observer -blind, two -stage, adaptive, multi -center study 
to evaluate the immunogenicity and safety of 2 doses of Panblok H7 at 3 dose levels of rHA 
(7.5 μg, 15 μg, and 30  μg) with the SE adjuvant compared to an unadjuvanted formulation (30  μg 
rHA) to determine in Stage 1 the optimal rHA dose level to be used in Stage 2 of t he study and to 
demonstrate in Stage 2 that the immunogenicity of the selected dose of adjuvanted Panblok H7 
meet the FDA criteria for licensure of a pandemic influenza vaccine ( 12). 
The rHA in Panblok H7 was derived from A/Anhui/1/2013 (H7N9) influenza virus strain. 
Panblok H7 was formulated in multidose vials containing 0.01% thimerosal as a preservative. 
Two doses, 21 days apart, were adminis tered by IM route in Stage I of the study in 407 healthy 
adults 18 years of age and older.  
Data from Stage 1 of PSC26 study showed that the adjuvanted and unadjuvanted Panblok H7 had 
an acceptable safety profile. The incidences of reported solicited inject ion site reactions after the 
first dose were somewhat higher in the adjuvanted vaccine groups, compared to the unadjuvanted 
vaccine group with solicited injection site pain and tenderness remaining consistently higher 
across all adjuvanted Panblok H7 group s compared to unadjuvanted Panblok H7 after Dose 2. 
Unsolicited AEs were low and similar in all groups, with no clinically concerning or unexpected 
events during the six weeks of follow -up after initial vaccination. There were no related deaths, 
SAEs, or o ther significant AEs among vaccine recipients.  No AESIs were reported in this study.  
The HAI immune responses to Panblok H7, either adjuvanted or unadjuvanted, were insufficient 
to support further enrollment into Stage  2 of the study.  
Study BARDA BP -I-17-002 
BARDA BP -I-17-002 study was a Phase II, randomized, double -blind study to evaluate the safety 
and immunogenicity of 2 doses of Panblok H7 at 3 dose levels (3.75, 7.5, and 15 μg) adjuvanted 
with either AS03 or MF59 to assess the safety of AS03 -adjuvanted  and MF59 -adjuvanted Panblok 
H7 and to evaluate the HAI immune response of the 3 dose levels of adjuvanted Panblok H7 ( 13). 
The rHA in Panblo k H7 was derived from A/Guangdong/17SF003/2016 (H7N9) influenza virus 
strain. Two doses, 28 days apart, were administered by IM route in 366 healthy adults 18 to 
< 50 years of age. The study vaccines were prepared by mixing Panblok H7 influenza vaccine 
antigen 1:1 with either MF59 or AS03 adjuvant prior to administration.  
Data from BARDA BP -I-17-002 study showed that adjuvanted Panblok H7 was safe and well 
tolerated across all vaccine groups. Within each adjuvant group, there were no notable differences 
in the safety profile between the 3 dose levels of adjuvanted Panblok H7 or between Dose 1 and 
Dose 2. The reactogenicity of adjuvanted Panblok H7 was similar across all vaccine groups, 
without notable difference between the rHA dose levels or adjuvants. No u nsolicited AEs, serious 
or non -serious, suggested a clinically significant safety issue with either vaccine dose or adjuvant. 
No deaths, potentially immune -mediated medical condition, AEs leading to early termination of 
vaccination, or AEs leading to study  withdrawal were reported during the entire study.  
AS03 -adjuvanted Panblok H7 was highly immunogenic at the 3 dose levels with the lower bound 
of the 95% CI for the percent of subjects achieving an HAI antibody titer ≥ 1:40 being above 70% 
at D50 and remai ning near or above 70% at D121 but decreasing substantially by D212. MF59 -
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 21 of 84 adjuvanted Panblok H7 was highly immunogenic in the 7.5 μg and 15 μg dose levels with the 
lower bound of the 95% CI for the percent of subjects achieving an HAI antibody titer ≥ 1:40  
being above 70% at D50 but decreased substantially by D121 and D212.  
 
2.3 Benefit/Risk Assessment   
More detailed information about the known and expected benefits and risks, reasonably expected 
adverse events, the potential risks, and uncertainties of Panblok  H7+ MF59 may be found in the 
IB. 
2.3.1 Risks from Study Participation   
The potential risks of clini cal significance and risk management are summarized in  Table  2.1. 
Table  2.1 - Identified and Potential risks of clinical significance and risk management   
Identified and 
Potential Risk of 
Clinical 
Significance  Summary of Data/Rationale for Risk  Risk Management  
Investigated Vaccines: Panblok H7 (7.5 µg) + MF59; Panblok H7 (15 µg) + MF59  
Comparator Vaccine: Panblok H7 (45 µg) unadjuvanted  
Anaphylactic 
reactions  Monitor non - important identified risk.  
All vaccines have the potential to cause 
allergic reactions or anaphylaxis in 
individuals who may be sensitized to 
components of the vaccine.  
Refer to IB Section  4.3 for more 
information regarding the components 
of the vaccine.  Observation period of 30  minutes after 
vaccination for early detection and 
treatment.  
Addre ssed in IB (administration 
precautions, potential adverse events), 
defined AESI in the study.  
Guillain -Barré 
syndrome  Important potential risk.  
Influenza vaccines have the potential to 
cause Guillain -Barré syndrome  Exclusion criterion E14 for those with 
personal or family history of Guillain -
Barré syndrome.  
Participants enrolling in the study will 
be informed of the potential AEs in the 
informed consent form (ICF) and will 
be advised to contact the study center 
to if a serious health problem occurs.  
Listed as AESIs in the study.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 22 of 84 Identified and 
Potential Risk of 
Clinical 
Significance  Summary of Data/Rationale for Risk  Risk Management  
Injection site 
reactions and 
systemic reactions  Monitor non -important identified risks.  
Injection site reactions such as redness, 
swelling, pain, bruising, and induration 
around the area wher e the vaccine was 
injected were observed. Systemic 
reactions such as headache, myalgia, 
arthralgia, fever, malaise, shivering, and 
fatigue were also observed.  
Most reactions resolved within 1 or 
2 days without treatment.  
Additional information on adverse 
reactions can be found in Section  7.1 of 
the IB.   Participants enrolling in the study will 
be informed of the potential adverse 
reactions in the ICF and will be 
advised to contact the study center if a 
serious health problem occurs.  
Study Procedures  
Vasovagal 
reactions 
(syncope), or 
psychogenic 
reactions to needle 
(vaccine injection 
or blood 
sampling)  Anxiety -related reactions can occur 
following, or even before, any 
vaccination as a psychogenic response 
to the needle injection or blood draw 
and may b e accompanied by several 
neurological signs such as transient 
visual disturbance, paresthesia or 
seizure -like activity.  Observation period of 30  minutes after 
vaccination or until resolution of 
related symptoms and normalization of 
all vital signs.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 23 of 84 Identified and 
Potential Risk of 
Clinical 
Significance  Summary of Data/Rationale for Risk  Risk Management  
Other  
Theoretical risk 
that participant 
can be exposed to 
severe acute 
respiratory 
syndrome 
coronavirus 2  
(SARS -CoV -2) 
infected 
individuals  SARS -CoV -2 virus is contagious. 
SARS -CoV -2 spreads through 
respiratory secretion or droplets. 
Transmission may also be possible via 
contaminated surfaces.  
Exposure can theoretically occur as a 
result of study procedures, including 
visits to the investigational sites and 
physical interactions with study staff.  Study site should minimize interactions 
between individuals when  visiting the 
study site.  
The site should establish routine 
cleaning procedures of commonly used 
areas to prevent the transmission of 
virus on contaminated surfaces.  
Personal protective equipment (eg, 
masks for participants and site staff, 
clothing, goggle s) to be used at sites.  
Home visit option for completion of 
study procedures in the setting of 
containment measures to minimize 
exposure.  
Participants will also be advised to 
adhere to local regulations and 
guidance (eg, self -isolation, social 
distancing) to minimize risk of 
exposure to SARS -CoV -2 infected 
individuals.  
Coronavirus Disease 2019 (COVID -19) Risk Assessment  
Panblok H7+MF59 is a vaccine against pandemic influenza. Panblok would not cause immune 
suppression. Therefore, the risk that a participan t in this study will contract COVID -19 solely due 
to the administration of the study intervention will be similar to the risk that a person not 
participating in this study will contract COVID -19. However, the risk of exposure to infected 
people cannot be c ompletely excluded as the participants may need to be exposed to public areas 
(eg, commute to/from the site and at the site).  
• Risk mitigation:  
• Not start the study until the local confinement measures or other safety restrictions linked 
to the COVID -19 pandemic are lifted by the local Authorities.  
• Continued risk assessment by the investigator and Sponsor before deciding to start the 
study.  
• Reduce the public exposure while ambulatory when possible.  
2.3.2 Benefits from Study Participation   
There may be no direct benefit from receiving Panblok H7+MF59. However, based on the data 
from previous studies ( 10) (11) (12) (13): 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 24 of 84 • Evaluation of the immunogenicity profile showed that many participants developed immune 
responses after 2 vaccine injecti ons 
• Safety evaluation indicated that this vaccine was well tolerated and no safety issues have been 
detected  
• Participants may benefit from potential protection against a future infection by the same, or 
very similar, A/H7N9 virus of avian origin  
As with an y vaccine, Panblok H7+MF59 may not protect 100% of individuals against the disease 
it is designed to prevent.  
2.3.3 Overall Benefit -Risk Conclusion   
Considering the measures taken to mi nimize risk to participants enrolled in this study, the 
potential risks that may result from study participation are balanced by the anticipated benefits 
that may be afforded to participants.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 25 of 84 3 Objectives and Endpoints   
The study objectives and the corresponding endpoints are described in Table  3.1. 
Table  3.1 - Objectives and endpoints   
Objectives  Endpoints  
Primary   
Immunogenicity  
To assess the antibody response induced 
by each study dose group of Panblok 
H7+MF59 vaccine (7.5 µg and 15  µg) 
compared with unadjuvanted Panblok H7 
(45 µg) by HIH and SN measurement 
methods at D22 and D43 (ie, 21 days after 
each v accination) in participants 
18 – 64 years and ≥  65 years of age  Immunogenicity  
The following immunogenicity endpoints will be described:  
Immunogenicity by HIH measurement method:  
• HAI Ab titers obtained on D22 and D43 for comparison 
with D01, D202, and D387  
• Individual HAI Ab titers ratio D22/D01 and D43/D01; 
and D202/D01 and D387/D01  
• Seroconversion defined as titer < 10 (1/dil) on D01 and 
post-injection titer ≥ 40 (1/dil) on D22 or D43; or 
defined as titer ≥  10 (1/dil) on D01 and a ≥  4-fold 
increase in titer  (1/dil) on D22 or D43  
• Individual HAI Ab titers ≥ 40 (1/dil) on D22 and D43; 
and D01, D202, and D387  
• Detectable HAI Ab titer, ie, with a titer ≥ 10 (1/dil) on 
D01, D22, D43, D202, and D387  
Immunogenicity by SN measurement method:  
• NT Ab titer obtained on D2 2 and D43 for comparison 
with D01, D202, and D387  
• Individual NT Ab titers ratio D22/D01, D43/D01, 
D202/D01, and D387/D01  
• NT Ab titers ≥ 20 (1/dil), ≥ 40 (1/dil), ≥  80 (1/dil) on 
D22 and D43; compared to D01, D202, and D387  
• Fold increase in NT Ab titer [post/pre] ≥  2 and ≥  4 on 
D22 and D43  
• Detectable NT Ab titer, ie, with a titer ≥ 10 (1/dil) on 
D01, D22, D43, D202, and D387  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 26 of 84 Secondary   
Safety  
To assess the safety profile in each 
study vaccine group in participants 
18 - 64 years and ≥  65 years of age 
throughout the study  Safety  
The following safety endpoints will be described:  
• Presence of any unsolicited systemic AEs reported 
in the 30  minutes after each vaccination  
• Presence of solicited (prelisted in the participant’s 
eDiary  and CRB) injection site reactions and 
systemic reactions occurring up to 7 days after 
each / any vaccination  
• Presence of unsolicited AEs up to 21 days after 
each / any vaccination  
• Presence of MAAEs throughout the study  
• Presence of AESIs throughout the stu dy 
• Presence of SAEs (including AESIs) throughout 
the study  
 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 27 of 84 4 Study Design   
4.1 Overall Design   
The design of the study is summarized in Table 4.1. 
Table 4.1 – Overall design   
Type of design  parallel, multi -center  
Phase  I / II 
Control method  active comparator  
(comparator = Panblok H7 (45 µg) unadjuvanted)  
Study population  healthy adults 18 years of age and older  
Level and method of blinding  modified double -blind  
Study intervention assignment method  randomizatio n 
Number of participants  Total of 700 participants  
 
Group 1 (Panblok H7 (7.5  μg) + MF59 ): 
150 participants 18 - 64 years of age  
150 participants 65 years of age and older  
Group 2 ( Panblok H7 (15  μg) + MF59 ): 
150 participants 18 - 64 years of age  
150 participants 65 years of age and older  
Group 3 (Panblok H7 (45 μg) unadjuvanted):  
50 participants 18 - 64 years of age  
50 participants 65 years of age and older  
Intervention groups  Eligible participants will be randomized in a 3:3:1 ratio 
and stratified i nto two age groups (18  - 64 years of age 
and ≥  65 years of age). The participants will receive 
2 doses, administered 21 days apart, by IM route of either 
Panblok H7 (7.5  µg) + MF59, Panblok H7 (15  µg) + 
MF59, or Panblok H7 (45  µg) unadjuvanted.  
Total dura tion of study participation  The study  duration for each participant will be 
approximately 13 months.  
Countries  United States  
Use of an Independent Data Monitoring 
Committee, Dose Escalation Committee, or 
similar review group  No 
 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 28 of 84 4.2 Scientific Rationale for  Study Design   
This is a Phase I  / II, randomized, modified double -blind study to assess the immunogenicity and 
safety  of the investigational vaccines with the goal of dose selection for the pivotal Phase III study 
in adults and the pediatric Phase I/II study.  
The study design will be a modified double -blind as the study will include adjuvanted  study 
vaccines that may hav e a different appearance than the unadjuvanted vaccine . Therefore, 
designated site staff involved in preparing and administering the vaccine would be unblinded. The 
investigator/Sub -investigator/staff involved in the safety assessment will be blinded in or der to 
decrease the risk of potential bias in safety assessment.  
Given most participants will be naïve in the case of a novel pandemic influenza strain, a dose 
schedule requiring 2 vaccinations, 21 days apart, will be evaluated in the study. Immune respons es 
after 1 or 2 vaccinations will be assessed by comparing immune responses at D43 versus D22.  
Vaccine -triggered immune responses against seasonal influenza vaccines diminish with advancing 
age due to immunosenescence (aging of the immune system) ( 14). Thus, participants will be 
enrolled in 2 age groups (18 - 64 years of age and 65 years of age and older) to evaluate the effect 
of age on the imm une responses and on safety of Panblok H7+MF59.  
This study will not include an early safety data review as the vaccine had an acceptable safety 
profile when administered to adults as shown in Study BARDA BP -I-17-002 and given prior 
clinical studies complet ed with similar Panblok formulations with different influenza strains. The 
safety of the adjuvant MF59 has also been established through the safety database of Seqirus’ 
adjuvanted seasonal influenza vaccine Fluad®. However, participants’ safety will be continuously 
monitored by the Sponsor’s internal safety review committee which includes safety signal 
detection at any time during the study. The study team will monitor the safety during the conduct 
of the study thr ough periodic Safety Management Team meetings as well as clinical data review 
meetings.  
4.3 Justification for Dose   
The 7.5 µg and 15 µg doses were selected based on data from Study BARDA BP -I-17-002 in 
which these 2 doses showed an immunogenic response without any safety issue. The addition of 
adjuvant is expected to increase antibody responses, but the dose -sparing potential of the adjuvant 
will be assessed by using age -matched contr ol groups of unadjuvanted vaccine (ie, Group 3).  
Based on data from previous clinical studies and given that most participants will be naïve in the 
case of a novel pandemic influenza strain, a dose schedule requiring 2 vaccinations, 21 days apart, 
will be evaluated in the study.  
4.4 End of Study Definition   
A participant is considered to have completed the immunogenicity evaluation in the study if 
he/she has completed the last visit of the study intervention phase (ie, V03)  planned in the SoA.  
The end of the study is defined as the date of the last visit of the last participant in the study.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 29 of 84 However, for periodic safety reports, the study is considered completed when the clinical study 
report is finalized.  
5 Study Population   
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not per mitted in this study.  
5.1 Inclusion Criteria   
Participants are eligible for the study only if all of the following criteria are met:  
Age 
I01: Aged 18 years or older on the day of incl usiona 
 
Type of participant and disease characteristics  
I02: Participants who are healthy as determined by medical evaluation including medical history 
and physical examination  
 
Sex, contracep tive/barrier method and pregnancy testing requirements  
I03: A female participant is eligible to participate if she is not pregnant or breastfeeding and one 
of the following conditions applies:  
• Is of non-childbearing potential. To be considered of non -child bearing potential, a female 
must be post -menopausal for at least 1 year, or surgically sterile.  
OR 
• Is of childbearing potential and agrees to use a highly effective contraceptive method or 
abstinence from at least 4 weeks prior to each study intervention administration until at 
least 12 weeks after the last study intervention administration.  
A female participant of childbearing potential must have a negative highly sensitive pregnancy 
test (urine or serum as required by local regulation) within 24 hours be fore the first dose of study 
intervention  
 
Informed Consent  
I04: Informed consent form has been signed and dated  
 
                                                 
a  “18 years” means from the day of the 18th birthday  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 30 of 84 OTHER INCLUSIONS  
I05: Able to attend all scheduled visits and to comply with all study procedures  
 
5.2 Exclusion Criteria   
Participants are not eligible for the study if any of the following criteria are met:  
Medical conditions  
E01:  Known or suspected congenital or acquired immunodeficiency; or receipt of 
immunosuppressive therapy, such as anti -cancer chemotherapy or radiation therapy, within the 
preceding 6 months; or long -term systemic corticosteroid therapy (prednisone or equivalent for 
more than 2 consecutive weeks within the past 3 months)  
E02: Known systemic hypersensi tivity to any of the study intervention components, or history of 
a life -threatening reaction to the study interventions used in the study or to a product containing 
any of the same substancesb 
E03:  Thrombocytopenia or bleeding disorder contraindicating intramuscular injection based on 
investigator’s judgment  
E04:  Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere 
with study conduct or completionc 
E05:  Neoplastic disease or any hematologic malignancy (except localized skin or prostate cancer 
that is stable at the time of study intervention administration in the absence of therapy, and 
participants wh o have a history of neoplastic disease and who have been disease -free for 
≥ 5 years)  
E06:  Moderate or severe acute illness/infection (according to investigator judgment) or febrile 
illness (temperature ≥ 100.4°F) on the day of study intervention administra tion. A prospective 
participant should not be included in the study until the condition has resolved or the febrile event 
has subsided  
E07: Alcohol, prescription drug, or substance abuse that, in the opinion of the investigator, might 
interfere with the st udy conduct or completion  
 
Prior/concomitant therapy  
E08: Receipt of any vaccine in the 14 days preceding Visit 1 or planned receipt of any vaccine 
prior to Visit 3 , except for seasonal flu vaccine, which may be received at least 2 weeks after 
Visit  2 
                                                 
b  The components of study interventions are listed in Section  6.1 of the protocol and in the Investigator’s Brochure.  
c  Chronic illness may include, but is not limited to, cardiac disorders, renal disorders, auto -immune disorders, 
diabetes, psychiatric disorders, or chr onic infection  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 31 of 84 E09:  Previous vaccination against H7N9 with an investigational vaccine  
E10: Receipt of immune globulins, blood or blood -derived products in the past 3 months  
 
Prior/concurrent clinical study experience  
E11: Participation at the time of study enrollment (or in the 4 weeks preceding the first study 
intervention administration) or planned participation during the present study period in another 
clinical study investigating a vaccine, drug, medical device, or med ical procedure  
 
Other exclusions  
E12:  Deprived of freedom by an administrative or court order, or in an emergency setting, or 
hospitalized involuntarily  
E13:  Identified as an Investigator or employee of the Investigator or study center with direct 
involvem ent in the proposed study, or identified as an immediate family member (ie, parent, 
spouse, natural or adopted child) of the Investigator or employee with direct involvement in the 
proposed study  
E14:  Personal or family history of Guillain -Barré syndrome  
E15:  Self-reported seropositivity for Hepatitis B antigen or Hepatitis C  
If the participant has a primary physician who is not the investigator, the site should  contact this 
physician with the participant’s consent  to inform him / her of the participant’s participation in the 
study. In addition, the site should ask this primary physician to verify exclusion criteria relating to 
previous therapies, such as receipt of blood products or previous vaccines.  
5.3 Lifestyle Considerations   
No other restrictions than the ones listed in the exclusion criteria or in the contraindications for 
subsequent vaccinations are required.  
5.4 Screen Failures   
A screen failure occurs when a participant who consents to participate in the clinical study is not 
subsequently randomly assigned to study intervention. Screening information is recorded in the 
source documents.  
Individuals who do  not meet the criteria for participation in this study (screen failure) can be 
rescreened.  
5.5 Criteria for Temporarily Delaying Enrollment, Randomization, 
Administration of Study Intervention, or Blood Samplings   
During a regional or national emergency declared by a governmental agency, if the site is unable 
to adequately follow protocol mandated procedures, contingency measures proposed in 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 32 of 84 Appendix  10.5: Contingency measures for a regional or national emergency that is declared by a 
governmental agency should be considered for enrollment, randomization, administration of 
study int ervention, or blood samplings.  
6 Study Interventions and Concomitant Therapy   
Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, 
or medical device(s) intended to be administered to a study participant according to the study 
protocol.  
Note: Vaccines or products administered outside of study protocol are not considered as study 
interventions and are reported in the CRF as reportable medi cations (see Section  6.8). Study 
procedures (eg, blood sampling) are also not considered as study interventions.  
6.1 Study Interventions Administered   
Study interventions are described in Table 6.1. 
Table 6.1 - Study interventions Administered   
Intervention 
Name  Panblok H7 (7.5  µg) 
+ MF59  Panblok H7 
(15 µg) + MF59  Panblok H7 (45  µg) 
unadjuvanted  
Use Experimental  Experimental  active comparator  
IMP and NIMP  IMP IMP IMP 
Type  Vaccine  Vaccine  Vaccine  
Dose Form  Suspension for injection 
in a vial  Suspension for injection 
in a vial  Liquid  for injection in a 
vial 
Unit Dose 
Strength  7.5 µg of rHA  of 
A/Guangdong/17SF003
/2016 (H7N9) with 9.75 
mg squalene of MF59 
adjuvant per dose  15 µg of rHA of 
A/Guangdong/17SF003/2
016 (H7N9) with 9.75 mg 
squalene of MF59 
adjuvant per dose  45 µg of rHA of 
A/Guangdong/17SF003/2
016 (H7N9) per dose  
Excipients/Diluent  0.01% Thimerosal in 
10 mM phosphate 
buffered saline with 
0.005% Polysorbate 80  0.01% Thimerosal in 
10 mM phosphate 
buffered saline with 
0.005% Polysorbate 80  0.01% Thimerosal in 
10 mM phosphate 
buffered saline with 
0.005% Polysorbate 80  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 33 of 84 Dosage Level(s)  0.5 mL per dose  0.5 mL per dose  0.5 mL per dose  
Number of Doses / 
Dosing Interval  2 doses, 21 days apart  2 doses, 21 days apart  2 doses, 21 days apart  
Route of 
Administration  IM injection  IM injection  IM injection  
Site of 
Administration  Deltoid muscle in  the 
upper arm  Deltoid muscle in the 
upper arm  Deltoid muscle in the 
upper arm  
Injection Site Side  Preferably the 
opposite arm from 
which blood was 
drawn  Preferably the opposite 
arm from which blood 
was drawn  Preferably the opposite 
arm from which blood 
was drawn  
Sourcing  Provided by the 
Sponsor  Provided by the Sponsor  Provided by the Sponsor  
Packaging and 
Labeling  Each study intervention will be provided in an individual box. Each study 
intervention will bear one fixed label and each box will bear one fixed label 
containing the treatment number. All will be labeled as required per country 
requirement.  
Current/Former 
Names or Aliases  Panblok  H7 +  MF59  Panblok  H7 +  MF59  Panblok H7 unadjuvanted  
Batch Number  TBD  TBD  TBD  
Storage 
Conditions  Study interventions will be stored in a refrigerator at a temperature ranging from 
+2°C to +8°C. The study interventions must not be frozen.  
IMP: Investigational Medicinal Product; NIMP: Non -Investigational Medicinal Product; TBD: to be determined  
 
6.2 Preparation,  Handling, Storage, and Accountability   
The study intervention should be allowed to reach room temperature before use. It must be shaken 
before use. Prior to administration, the s tudy intervention must be inspected visually for cracks, 
broken seals, correct label content, and extraneous particulate matter and / or discoloration, 
whenever solution and container permit. If any of these conditions exists, the study intervention 
must n ot be administered. Another dose is to be used, and the event is to be reported to the 
Sponsor.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 34 of 84 The study intervention is to be administered intramuscularly into the deltoid muscle (preferably on 
the opposite arm from which blood was drawn before vaccinati on). 
Participants must be kept under observation for 30 minutes after vaccination to ensure their safety, 
and any reactions during this period will be documented in the CRF.  
 
1) The investigator or designee must confirm appropriate temperature conditions have  been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention.  
2) Only participants enrolled in the study may receive study intervention and only authorized 
site staff may supply or administer study intervention. All study intervention must be stored 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator a nd 
authorized site staff.  
3) The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposit ion records).  
4) Further guidance and information for the final disposition of unused study interventions will 
be provided to the study personnel.  
6.3 Measures to Minimize Bias: Randomization and Blinding   
6.3.1 Randomization and Allocation Procedures   
Randomization of participants will be performed with the blocked method, with stratification by 
age stratum. Each part icipant who meets all the inclusion criteria and none of the exclusion 
criteria and signs the ICF will be randomly assigned according to the participant’s age group, to 
either Group 1, Group 2, or Group 3 via an interactive response technology (IRT) system , 
according to a 3:3:1 ratio.  
Before vaccination,  authorized qualified study staff  will connect to the IRT system , enter the 
identification and security information, and confirm a minimal amount of data in response to IRT 
system  prompts. The IRT system  will then provide  the vaccine dose identification number. 
Participant numbers and vaccine dose identification numbers will be recorded in the eCRF.  
The full detailed procedures for group allocation are described in the IRT User Guide . If the 
participant is no t eligible to participate in the study, then the information will only be recorded on 
the participant recruitment log.  
If the dose initially allocated for vaccination cannot be used (eg, because the syringe broke or 
particulate matter was observed), author ized qualified study staff will obtain a replacement dose. 
Thus, the site personnel must contact the IRT system to receive the replacement dose allocation.  
Participant numbers that are assigned by the  IRT will consist of a 12 -digit string (a 3 -digit countr y 
identifier, a 4 -digit study  center identifier, and a 5 -digit participant identifier). For example, 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 35 of 84 Participant  840000100005 is the fifth participant enrolled in Center Number  1 in the US (840 
being the US country code).  
Participant numbers should not be reassigned for any reason. The randomization codes will be 
kept securely in the IRT and an internal system.  
6.3.2 Blinding and Code -breaking Procedures   
The study will be conducted  in a modified double -blind fashion:  
• Investigators and study staff who conduct the safety assessment, laboratory personnel who 
analyze the blood samples, Sponsor’s personnel and study Team members, and  the participant 
will not know which study intervention  is administered  
• Only the study staff who prepare and administer the study intervention and are not involved 
with the safety evaluation will know which study intervention is administered  
The investigator responsible for safety assessment will not attend th e vaccination session but will 
be available in case of emergency (eg, anaphylactic shock).  
Dose numbers will be used to identify each vaccine vial for the purpose of randomization, 
vaccination, and the recording of vaccine dose administered. Dose numbers w ill be randomly 
assigned to the 3 study interventions. The IRT vendor will be responsible for providing the 
participant identification and dose number to be received by the enrolled participant.  
The code may be broken in the event of an AE only when the id entification of the study dose 
intervention received could influence the treatment of the participant. Code -breaking should be 
limited to the participant(s) experiencing the AE.  
The blind can be broken by the investigator or a designee through the IRT syst em. Once the 
emergency has been addressed by the site, the investigator or a designee must notify the Sponsor’s 
RMO if a participant’s code was broken. All contact attempts with the Sponsor prior to unblinding 
are to be documented in the source documents, and the code -breaking CRF is to be completed.  
The Institutional Review Board (IRB)/Independent Ethics Committee (IEC)  must be notified of 
the code -breaking, in accordance with local regulations. All documentation pertaining to the event 
must be retained in  the site’s study records and in the Sponsor’s files. Any intentional or 
unintentional code -breaking must be reported, documented, and explained, and the name of the 
person who requested it must be provided to the Sponsor.  
A request for the code to be brok en may also be made:  
• by the Global Pharmacovigilance (GPV) Department through an internal system for 
reporting to Health Authorities in the case of an unexpected SAE considered causally 
related, as described in International Council for Harmonisation (ICH)  E2A. In this case, 
the code will be broken only for the participant(s) in question. The information resulting 
from code -breaking (ie, the participant’s study intervention or group assignment) will not 
be communicated to either the investigator or the imme diate team working on the study, 
except for the GPV representative.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 36 of 84 At the time of the interim analysis (see Section  9.5), study unblinding will take place to inform 
selection of the dose formulation for Phase III clinical development. The unblinding code data 
will be maintained with the Sponsor until the end of the study. The study team will strive not to 
communicate  the study unblinding data to sites in order to minimize bias in collecting the follow -
up safety data. The study participants and the laboratory personnel who analyze the blood samples  
for the study will remain blinded throughout the study.  
6.4 Study Intervent ion Compliance   
The following measures will ensure that the study intervention is administered as planned (see 
Table 6.1), and that any non -compliance is documented so that it can be accounted for in the data 
analyses:  
• All study interventions will be administered by qualified and trained study personnel  
• The person in charge of s tudy intervention management at the site will maintain 
accountability records of study intervention delivery to the study site, study intervention 
inventory at the site, dose(s) given to each participant, and unused or wasted doses  
For a regional or nation al emergency declared by a governmental agency that results in travel 
restrictions, confinement, or restricted site access, contingency measures are included in 
Appendix  10.5: Contingency Measures for a regional or national emergency that is declared by a 
governmental agency.  
6.5 Dose Modification   
Not applicable.  
6.6 Continued Access  to Study Intervention After the End of the Study   
Not applicable.  
6.7 Treatment of Overdose   
Since the st udy intervention is administered by a health care professional, it is unlikely that 
overdose by injection occurs.  
However, in the event of an overdose, the investigator should:  
1) Contact the RMO immediately.  
2) Evaluate the  participant to determine, in consultation with the RMO, whether study 
intervention should be interrupted.  
3) Closely monitor the participant for any AE/SAE.  
4) Document the quantity of the excess of the overdose in the source documents.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 37 of 84 6.8 Concomitant Therapy   
At the time of enrollment, ongoing medications and other therapies (eg, blood products) should be 
recorded in the source document as well as new medications prescribed for new medica l 
conditions / AEs during study participation.  
Documentation in the CRF of ongoing concomitant medication(s) will be limited to specific 
categories of medications of interest beginning on the day of first vaccination.  
Reportable medications include medicat ions that may affect the interpretation of safety data (eg, an 
antipyretic or analgesic that could have reduced the intensity or frequency of an adverse event) or 
may interfere with the development or measurement of the immune response (eg, the use of 
immu ne-suppressors, immune -modulators, or some antibiotics that can affect certain bioassays). 
Some medications such as steroids can affect both the evaluation of the safety and the immune 
response to a vaccine.  
This may include medications of interest that we re started prior to the day of vaccination, and 
even stopped prior to enrollment if there is a reasonable possibility that they may have an impact 
on safety and / or immune assessment during study participation.  
The following reportable medications are def ined:  
• Medications impacting or that may have an impact on the evaluation of the safety (eg, 
antipyretics, analgesics, and non -steroidal anti -inflammatory drugs, systemic 
steroids/corticosteroids)  
Note: Topical analgesics should NOT be applied at the inject ion site of study intervention; 
however, if they are applied inadvertently, they should be recorded.  
• Medications impacting or that may have an impact on the immune response (eg, other 
vaccines, blood products, antibiotic classes that may interfere with bio assays used by the 
Sponsor’s laboratory or other testing laboratories, systemic steroids/corticosteroids, 
immune -suppressors, immune -modulators with immunosuppressive properties, anti -
proliferative drugs such as DNA synthesis inhibitors)  
• Medications impact ing or that may have an impact on both the safety and the immune 
response (eg, systemic steroids/corticosteroids)  
Reportable medications will be collected in the CRF until the end of the solicited and unsolicited 
follow -up period.  
Dosage and administration  route, homeopathic medication, topical and inhaled steroids, as well as 
topical, ophthalmic, and ear treatments will not be recorded (except  topical analgesics applied at the 
injection site of study intervention ). However, in case of an SAE, all medicatio ns and supplements 
including homeopathic medications taken for the SAE should be reported in the SAE form . 
Medications given in response to an AE will be captured in the “Action Taken” section of the AE 
CRF only. No details will be recorded in the concomit ant medication Form of the CRF unless  the 
medication(s) received belongs to the reportable medications list. Medications will be coded using 
the WHODrug dictionary.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 38 of 84 6.8.1 Rescue Medicine   
Appropriate medical equipment and emergency medications, including epinephrine (1:1000), 
must be available at the study site in the event of an anaphylactic, vasovagal, or other immediate 
allergic reaction.  
7 Discontinuation of Study Intervention and Part icipant 
Discontinuation/Withdrawal   
Discontinuation of specific sites or of the study as a whole are detailed in Appendix 10.1. 
7.1 Discontinuation of Study Intervention   
7.1.1 Temporary Contraindications   
Should a participant experience one of the conditions listed below, the investigator will postpone 
further vaccination until the condition is resolved. Postponement must still b e within the 
timeframe for vaccination indicated in the SoA.  
If the postponement occurs out of the timeframe for vaccination, the participant will be 
permanently discontinued from study intervention but will continue to be followed for safety and 
will not have any further blood sample drawn.  
TCI01:  Moderate or severe acute illness/infection (according to investigator judgment) or 
febrile illness (temperature ≥ 100.4°F) on the day of study intervention administration. 
A prospective participant should not be include d in the study until the condition has 
resolved or the febrile event has subsided  
Temporary intervention discontinuation may be considered by the investigator because of 
suspected AEs or disruption of the clinical study due to a regional or national emerge ncy declared 
by a governmental agency ( Appendix 10.5: Contingency Measures for a regional or national 
emergency that is declared by a governmental ag ency). For all temporary intervention 
discontinuations, duration should be recorded by the investigator in the source documents . 
In the event of a local or national immunization program with a SARS -CoV -2 or other vaccine , 
participants who receive these vac cines at any time during the study will not be withdrawn from 
the study.  
7.1.2 Definitive Contraindications   
Participants will permanently discontinue (definitive discontinuation) study  intervention for the 
reasons listed below. These participants must not receive any additional dose of study intervention 
but should continue to be followed for safety and will not have any further blood sample drawn. 
Additional unscheduled visits may be p erformed for safety  reasons and information will be 
reported in the source documents.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 39 of 84 Should a participant experience at least one of the conditions listed below, the investigator will 
discontinue vaccination:  
DCI01:  Pregnancy, as indicated by a positive urine te st (if applicable)  
DCI02:  An anaphylactic or other significant allergic reaction to the previous dose of vaccine  
DCI03:  SAE assessed as related to the study vaccine following the previous dose of vaccine, 
based on Investigator’s judgment  
DCI04:  Receipt of any immune globulins,  blood, or blood -derived products between V01 and 
V02 
DCI05:  Known or suspected congenital or acquired immunodeficiency; or receipt of 
immunosuppressive therapy, such as anti -cancer chemotherapy or radiation therapy, 
since the preceding visit; or long -term system ic corticosteroid therapy (prednisone or 
equivalent for more than 2 consecutive weeks since the preceding visit)  
DCI06:  Thrombocytopenia or bleeding disorder, which may be a contraindication for IM 
vaccination, based on Investigator’s judgment  
DCI07:  Chronic illness tha t, in the opinion of the investigator, is at a stage where it might 
interfere with study conduct or completion  
DCI08:  Development of any condition that in the opinion of the Investigator would pose a 
health risk to the subject or could interfere with the evaluati on of the study 
intervention (including Guillain -Barré syndrome, hepatitis B, or hepatitis C)  
In the event of a local or national immunization program with a SARS -CoV -2 or other vaccine , 
participants who receive these vaccines at any time during the study will not be withdrawn from 
the study.  
7.1.3 Other Reasons   
A participant may discontinue from study intervention at any time at his/her own request, or at the 
discretion of the investig ator for safety, behavioral, or compliance reasons.  
Participants should continue to be followed for safety and will not have any further blood sample 
drawn . 
 
7.2 Participant Discontinuation/Withdrawal from the Study   
• A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, or 
compliance reasons. This is expected to be unco mmon.  
• The reason for withdrawal should be clearly documented in the source documents and in the 
CRF . 
• The participant will be permanently discontinued from the study intervention and from the 
study at that time. However, the site should attempt to contact them and complete all 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 40 of 84 scheduled safety follow -ups, except if they specified that they do not want to be contacted 
again and it is documented in the source document.  
• If the participant withdraws consent for disclosure of future information, the Sponsor will  
retain and continue to use any data collected before such a withdrawal of consent.  
• If a participant withdraws consent, he/she may request destruction of any biological samples 
taken (unless local law requires not to destroy them), and the investigator mus t document this 
in the site study records.  
• Withdrawn participants will not be replaced.  
7.3 Lost to Follow -up  
In the case of participants who fail to return for a follow -up examinati on, documented reasonable 
effort (ie, documented telephone calls and certified mail) should be undertaken to locate or recall 
them, or at least to determine their health status while fully respecting their rights. These efforts 
should be documented in the CRF and in the source documents.  
A participant  will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions must be taken if a participant fails to return to the site for a required study 
visit or cannot be contacted as planned in the SoA:  
• The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible, counsel the participant on the importance of maintaining the a ssigned visit schedule, 
and ascertain whether the participant wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee must make every 
effort to regain contact with the participant (where  possible, 3 telephone calls and, if 
necessary, a certified letter to the participant’s last known mailing address or local equivalent 
methods). These contact attempts should be documented in the participant’s medical record.  
• Should the participant continu e to be unreachable, he/she will be considered lost to follow -up. 
8 Study Assessments and Procedures   
• Study procedures and their timing are summarized in the SoA. Protocol  waivers o r 
exemptions are not allowed.  
• Immediate safety concerns should be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue study 
intervention.  
• Adherence to the study design requireme nts, including those specified in the SoA, is essential 
and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screenin g log to 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 41 of 84 record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
• Safety  / laboratory results that could unblind the study will not be reported to sites or other 
blinded personnel until the study has been unblinded.  
Urine (as applicable) and blood  samples will be collected as described in the SoA table 
(Section  1.2). 
The maximum amount of blood collected from each participant over the duration of the study, 
including any extra assessments that may be required, is not planned to exceed 240 mL. Repeat or 
unscheduled samples may be taken for safety reasons or for technical issues with the samples.  
Guidance and information for the sample collection, preparation, storage, and shipment will be 
provided to the study personnel.  
For a regional or national emergency declared by a governmental agency, contin gency measures 
are included in Appendix 10.5: Contingency Measures for a regional or national emergency that is 
declared by a governmental agency.  
8.1 Efficacy and Immunogenicity Assessments   
Planned time points for all immunogenicity  assessments are provided in the SoA.  
8.1.1 Efficacy Assessments   
No clinical efficacy data will be obtained in the study.  
8.1.2 Immunogenicity Assessments   
Assays will be performed by the Sponsor’s laboratory (Swiftwater, PA, USA) . 
Immunogenicity will be evaluated using samples taken before each vaccination (ie, D01 and D22 
[+7 days]), and at D43 (+7 days), D202 (+14 days), and D387 (+14 days) after the first 
vaccination us ing the HIH and SN assays.  
Anti-Influenza Virus Antibody Titration by Inhibition of Hemagglutination using Horse Red 
Blood Cells (HIH)  
The influenza virus HIH assay is based on the ability of specific anti -influenza antibodies to 
inhibit agglutination of h orse red blood cells (HRBCs) induced by influenza virus HA. The sera 
are pre -treated to eliminate the non -specific inhibitors. Serial dilutions of sera are incubated with a 
fixed amount of influenza virus. Antibodies present in the serum sample will inhibi t the 
agglutination of HRBCs when influenza virus is added. The endpoint of the assay is the highest 
serum dilution in which complete inhibition of hemagglutination occurs.  
 
 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 42 of 84 Influenza Virus Neutralization Test (also known as SN Assay)  
The influenza virus neutralization test measures Abs directed against the viral neutralization 
epitopes of the influenza virus, which may be different from the hemagglutination epitopes, 
therefore, the NT titers may be different from the HAI titers.  
Two-fold serially diluted,  heat-inactivated human serum samples will be pre -incubated with a 
fixed amount of challenge virus prior to the addition of Madin -Darby canine kidney (MDCK) 
cells. After overnight incubation, the viral nucleoprotein production in infected MDCK cells is 
measured by enzyme -linked immunosorbent assay (ELISA), using monoclonal Ab specific to 
influenza A nucleoprotein. Since serum neutralizing Abs to the influenza virus inhibits the viral 
infection of MDCK cells, the ELISA optical density results are inversely p roportional to the titers 
of neutralizing Ab present in the serum. The lower limit of quantitation is set at the reciprocal of 
the lowest dilution used in the assay, ie, 10 (1/dil). Titers below this level are reported as <  10 
(1/dil). Titers >  10240 (1/di l) will be pre -diluted, retested, and end point titers will be reported.  
8.2 Safety Assessments   
This section presents safety assessments other than AEs which are presented in Section  8.3. 
Planned timepoints for all safety assessments are provided in the SoA ( Section  1.2). 
8.2.1 Medical History   
Prior to enrollment, participants will be assessed for pre -existing conditions and illnesses, both 
past and ongoing. Any such  conditions will be documented in the source document. Significant 
(clinically relevant) medical history (reported as diagnosis) including conditions/illnesses for 
which the participant is or has been followed by a physician or conditions/illnesses that co uld 
resume during the course of the study or lead to an SAE or to a repetitive outpatient care will be 
collected in the CRF. Collected information will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA).  
8.2.2 Physical Examinations   
At Visit 1 and Visit 2, the investigator or a designee will perform a clinical or medically -driven 
physical examination. Information will be recorded in the source document and in the CR F. 
8.2.3 Vital Signs   
Oral pre-vaccination temperature will be systematically collected  by the investigator on the source 
document. Tympanic, skin, and temporal artery thermometers must not be used.  
8.2.4 Clinical Safety Laboratory Tests   
Not applicable.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 43 of 84 8.2.5 Pregnancy Testing   
Urine pregnancy testing will be performed in women of childbearing potential before each 
vaccination. See Appendix  10.2 and the SoA ( Section  1.2) for the timing and frequency.  
8.3 Adverse Events (AEs), Serious Adverse Events, and Other Safety Reporting   
The definitions of an AE, SAE, and the different categories of AEs can be found in 
Appendix  10.3. 
AEs will be reported by the participants to the investigator, then by the investigator to the 
Sponsor . 
The investigator and any qualified designees are responsibl e for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study intervention or study procedures, or that 
caused the participant to di scontinue the study intervention and / or study (see Section  7). 
The method of recording, evaluating, and assessin g causality of AEs and SAEs and the procedures 
for completing and transmitting SAE reports are provided in Appendix 10.3. 
8.3.1 Time Period and Frequency for Collecting AE and SAE Information   
Immediate Post -vaccination Observation Period  
Participants will be kept under observation for 30 minutes after each vaccination to ensure their 
safety. The post -vaccination observation should be documented in the source document.  
Reactogenicity  
Solicited injection site reactions will be collected from the day of vaccination (DX) until 7 days 
after each vaccination (DX + 7 days).  
Solicited sy stemic reactions will be collected from the day of vaccination (DX) until 7 days after 
each vaccination (DX + 7 days).  
The solicited injection site reactions and systemic reactions that are pre -listed in the eDiary  and 
CRF, together with the intensity scal es, are presented in Appendix  10.3.5.1.1 . 
Unsolicited Non -serious Adverse Events  
Unsolicited non -serious adverse events will be collected from the da y of vaccination (DX) until 
21 days after each vaccination (DX + 21 days).  
The intensity grading scale for unsolicited non -serious adverse events is presented in 
Appendix  10.3.5.1.2 . 
Medically Attended Adverse Events (MAAEs)  
MAAEs will be collected throughout the study.  
Adverse Events of Special Interest (AESIs)  
AESIs will be collected throughout the study.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 44 of 84 See Section  8.3.6  for the list of AESIs.  
SAEs  
Information on SAEs will be collected and assessed throughout the study, from the first study 
intervention admini stration until  12 months after the last vaccination. However, before the first 
study intervention administration, only SAEs related to study procedures are to be collected in the 
CRF (eg, SAEs related to blood sampling).  
All SAEs will be recorded and repor ted to the S ponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Appendix  10.3. The investigator will 
submit any updated SAE data to the Sponsor within 24 hours of it being available.  
Investigators are not obligated to actively seek information on AEs or SAEs after conclusion of 
the study participation . However, if the investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study intervention or study participation, the investigator must promptly 
notify the Sponsor . 
8.3.2 Method of Detecting AEs and SAEs   
Individual eDiary, specifically designed for this study by the Sponsor  and provided to the study 
sites, will be available to study participants for the recording of daily safety information. The 
eDiary is the primary method for safety data collection. However, paper diary cards will also be 
available for use as a back -up sol ution in case of major breakdown of the app or as determined by 
the Sponsor’s study clinical team. The eDiary will include pre -listed terms and intensity scales as 
well as areas for free text to capture additional safety information or other relevant detai ls. 
Participants will also be provided with rulers for measuring the size of injection site reactions, and 
with standard digital thermometers for measuring daily temperatures. To ensure consistency of 
reporting, the study sites will instruct participants o n how to correctly use these tools.  
At specified intervals, the investigator or a designee will interview the participants to confirm the 
information recorded in the eDiary, and will attempt to clarify anything that is incomplete or 
unclear. All clinical s tudy information gathered by the study site will be reported electronically 
using a web -based CRF. Any information that was not documented in the eDiary will first be 
captured in the source document and then reported electronically.  
The 12 -month follow -up should be done at least 365  days after the last vaccination for all 
participants having received at least one dose of the study intervention, by interviewing 
participants during Visit 5 (or over the telephone if the visit cannot be performed in -person) usi ng 
a questionnaire to capture MAAEs, SAEs, and AESIs, if applicable.  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occur rences.  
8.3.3 Follow -up of AEs and SAEs   
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts, unless a par ticipant refuses further contact . All AEs that are 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 45 of 84 considered by the investigator as serious, or related to the study intervention administered, or that 
led to study or vaccination discontinuation,  or AESIs (as defined in Section  8.3.6 ), will be 
followed during the conduct of the study until resolution, stabilization, or the participant is lost to 
follow -up (as defined in Section  7.3). For related SAEs ongoing at last study visit, such follow -up 
may need to continue after the end of the study.  
Further information on follow -up procedures is provided in Appendix 10.3. 
8.3.4 Regulatory Reporting Requirements for SAEs   
• Prompt notification by the investigator to the Sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a 
study intervention under clinical investigation are met.  
• The Sponsor has a legal responsibility to notify both the local regulato ry authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply with country -specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRB/IEC , and i nvestigators.  
• An investigator who receives an investigator safety report describing a SAE or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will review and then 
file it and will notify the IRB/IEC, if appropriate accord ing to local requirements.  
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSARs) according to local regulatory requirements and Sponsor policy and 
forwarded to investigators as necessary.  
8.3.5 Pregnancy   
Pregnant women are not eligible to participate in the study and women of childbearing potential 
agree to use an effective contraceptive method, as defined in the inclusion criteria. How ever, a 
participant could potentially become pregnant during her participation.  
• Details of all pregnancies in female participants will be collected in the GPV database after the 
start of study intervention and until  delivery in the GPV database.  
• If a pregn ancy is reported, the investigator should promptly inform the Sponsor and will 
record pregnancy information together with the contraceptive method on the appropriate form 
and submit it to the Sponsor within 1 month  of learning of the pregnancy.  
• While pregn ancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
• Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congen ital 
anomalies, ectopic pregnancy) are considered SAEs and will be reported as such.  
• The participant will be followed to determine the outcome of the pregnancy. The investigator 
will collect follow -up information on the participant and the neonate and the information will 
be forwarded to the Sponsor. Generally, follow -up will be required for at least 6 months to 
1 year beyond the estimated delivery date, but will be in accordance with local regulations. 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 46 of 84 Any termination of pregnancy will be reported, regardl ess of fetal status (presence or absence 
of anomalies) or indication for the procedure.  
• Any post -study pregnancy -related SAE considered reasonably related to the study intervention 
by the investigator will be reported to the Sponsor as described in Section  8.3.4 . While the 
investigator is not obligated to actively seek this information in former study participants, he  
or she may learn of an SAE through spontaneous reporting.  
• Any female participant who becomes pregnant while participating in the study will 
discontinue study intervention until delivery or until delivery and end of lactation. However, 
the participant will  be followed for safety assessment (and may be followed for 
immunogenicity assessment, if applicable).  
8.3.6 Adverse Events of Special Interest   
AESIs will be captured as SAEs and will be collected throughout the study. These include 
anaphylactic reactions, Guillain -Barré syndrome, encephalitis / myelitis (including transverse 
myelitis), Bell’s palsy, thrombocytopenia, optic neuritis, brachial neuritis, and vasculitis ( 15) (16) 
(17). 
8.3.7 Medically Attended Adverse Events   
MAAEs will be collected using the same process as other AEs. See Appendix  10.3.1  for definition 
of MA AEs.  
8.4 Pharmacokinetics   
Pharmacokinetics parameters are not evaluated in this study.  
8.5 Genetics   
Genetics  are not evaluated in this study.  
8.6 Biomarkers   
No other biomarkers than those described in the immunogenicity assessments section 
(Section  8.1.2 ) are evaluated in this study.  
8.7 Immunogenicity Assessments   
See Section  8.1.2 . 
8.8 Medical Resource Utilization and Health Economics   
Medical Resource Utilizatio n and Health Economics parameters are not evaluated in this study.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 47 of 84 8.9 Leftover Biological Samples and Use of Data   
Any unused part of the biological samples (ie, serum samples)  colle cted for this study are being 
retained in long -term storage to support answers to regulatory questions related to the product’s 
licensure and the potential revalidation of the study results.  
In addition, participants will be asked to indicate in the ICF wh ether they will permit the future 
use of any unused stored biological samples for other tests and the corresponding data, unless 
prohibited by local laws or IRBs/IECs (in such case, consent for future use of any unused 
biological samples will not be includ ed in the site -specific ICF). If they refuse permission, the 
biological samples will not be used for any testing other than that directly related to this study. If 
they agree to this future use, they will not be paid for giving permission. Data and samples  will be 
used in compliance with the information provided to participants in the ICF Part 2 (future 
research). The aim of any possible future research is unknown today and may not be related to this 
particular study. It may be to improve the knowledge of v accines and their mechanism of action, 
the knowledge of infectious diseases, or to improve existing tests or develop new tests to assess 
vaccines, or to help identify new vaccine targets or biomarkers that predict participant response to 
the vaccine. Such research may also include, but is not limited to, performing assessments on 
DNA, RNA, proteins or metabolites. If future research on genetic material is performed, a specific 
individual consent will be obtained.  
All study participant data and biological sa mples will be coded such that no direct identifiers will 
be linked to participants. Coded data and biological samples may be transferred to a Sponsor site 
(or a subcontractor site), which may be located outside of the country where the study is 
conducted. The Sponsor adopts safeguards for protecting participant confidentiality and personal 
data (see Section  10.1.4 ). 
The biological samples will be securely stored at the Sanofi Pasteur laboratory or contract 
Research Laboratory up to 25 years after the end of the study. Any samples remaining at the end 
of retention period will be destroyed. If a participant requests des truction of his/her samples 
before the end of the retention period, the investigator must notify the Sponsor (or its contract 
organization) in writing. In such case, samples will be destroyed and sample related coded data 
will be anonymized unless otherwis e required by applicable laws.  
Study participant coded data will be stored for future research for up to 25 years after the end of 
the study. If data are still considered of important scientific value after this period, coded data 
already available will be  anonymized unless otherwise required by applicable laws (the same will 
apply to the data of a study participant who has requested the destruction of his/her samples).  
Participant’s coded data sets provided to researchers for a specific research project wi ll be 
available to the researchers for a maximum of 2 years after the end of their specific project (end of 
project is defined by publication of the results or finalization of the future research project report).  
Note: The other biological samples collecte d to qualify the participant for inclusion in the study 
are dedicated for immediate use. If any of these biological samples are not completely used up, 
they will be destroyed at the latest at the end of the study or after the time requested by local law.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 48 of 84 9 Statistical Considerations   
All statistical analyses will be performed under the responsibility of the Sponsor’s Biostatistics 
Platform using the SAS® software, Version 9.4 or abov e. 
The SAP core body will be written and peer -reviewed before the initiation of the study. In 
accordance with the protocol, the SAP core body will describe all analyses to be performed by the 
Sponsor.  
For descriptive purposes, the following statistics will  be presented:  
Table 9.1 - Descriptive statistics produced   
Baseline characteristics 
and follow -up 
description  Categorical data  Number and percentage of participants  
Continuous data  Mean, standard deviation, quartiles, minimum, and 
maximum  
Safety results  Categorical data  Solicited and biological safety: Number and percentage 
(95% CIs) of participants  
Unsolicited: Number and percentage (95% CIs) of 
participants, and number of events  
Continuous data  At least mean, standard deviation, minimum, and 
maximum  
Immunogenicity results  Categorical data (such 
as seroconversion)  Number and percentage (95% CIs) of participants  
Continuous data  
(titer / data)  Log 10: Mean and standard deviation  
Anti-Log 10 (work on Log 10 distribution, and anti -Log 10 
applied): Geometric mean, 95%  CI of the geometric 
mean, quartiles, minimum, and maximum  
Graphical representation by RCDC  
 
9.1 Statistical Hypotheses   
No hypotheses will be tested in this study.  
9.2 Sample Size Determination Based on HAI Data   
Assuming a dropout rate of approximately 10%, a total of approximately 630 participants 
evaluable for immunogenicity is anticipated.  
Table 9.2 shows the expected number of evaluable participants in each study group and each age 
stratum, and the probability that the lower bound of the 95% CI exceeding the threshold defined 
by Center for Biologics Evaluation and Research (CBER) requirement for seroconversion and 
percentage of subjects achieving an HAI antibody titer ≥ 1:40 ( 18). 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 49 of 84 Table 9.2 - Probability calculation   
Age in Years  Evaluable Number of 
Participants (Study 
Group)  Expected 
Proportion  CBER: Lower 
Bound of 2 -Sided 
95% CI Greater 
Than  Probability 
(%) 
Percent of participants with HAI antibody titer ≥  1:40 
≥ 18 270 (Groups 1 or 2)  0.80 70% 96% 
18 to <  65  135 (Groups 1 or 2)  0.82 70% 88% 
≥ 65 135 (Groups 1 or 2)  0.72 60% 82% 
≥ 18 90 (Group 3)  0.85 70% 93% 
18 to <  65  45 (Group 3)  0.85 70% < 80% 
≥ 65 45 (Group 3)  0.80 60% 83% 
Percent of participants with seroconversion for antibody  
≥ 18 270 (Groups 1 or 2)  0.50 40% 90% 
18 to <  65 135 (Groups 1 or 2)  0.52 40% <80%  
≥ 65 135 (Groups 1 or 2)  0.42 30% 82% 
≥ 18 90 (Group 3)  0.55 40% 80% 
18 to <  65  45 (Group 3)  0.70 40% 97% 
≥ 65 45 (Group 3)  0.50 30% <80%  
 
9.3 Analysis Sets   
For the purposes of analysis, the following analysis sets are defined:  
Participant Analysis 
Set Description  
Randomized  All participants randomized by study IRT to one of the 3 study doses 
(one of three study groups).  
Safety Analysis Set (SafAS)  Participants who have received at least one study intervention.  
All participants will have their safety analyzed after each dose 
according to the intervention actually received, and after any dose 
according to the intervention received at the 1st dose. Safety data 
recorded for a vaccine received out of the protocol design will be 
excluded from the analysis (and listed separately).  
Full analysis set (FAS)  Subset of randomized particip ants who received at least 1 dose of the 
study vaccine and had a post -vaccination blood sample for D22 or D43.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 50 of 84 Participants will be analyzed according to the study dose group to which 
they were randomized.  
Per-protocol analysis set 
(PPAS)  To be able to compare and present the results of immunogenicity in the 
same table, only one PPAS will be derived in this study.  
Subset of the FAS participants who have provided D22 and D43 blood 
samples. Participants presenting with at least one of the following 
relevan t protocol conditions will be excluded from the PPAS:  
• Participant did not meet all protocol -specified inclusion criteria 
or met at least one of the protocol -specified exclusion criteria  
• Participant did not complete the vaccination schedule  
• Participant rece ived a vaccine other than the one that he / she 
was randomized to receive  
• Preparation and / or administration of vaccine was not done as 
per-protocol  
• Participant did not receive vaccine in the proper time window  
• Participant did not provide a post -dose sero logy sample at D22 
(+7 days) and D43 (+7 days)  in the proper time window or a 
post-dose serology sample was not drawn  
• Participant received a medication impacting or that may have an 
impact on the immune response as described in Section  6.8 
• Re-randomized participants  
Any other deviation identified during the study conduct and judged by 
the clinical team during data revi ew as having a potential impact on the 
assessment of immunogenicity will be used to exclude a participant 
from the PPAS.  
Participants with missing SN data or participants with no valid test 
results of SN will be included in PPAS if they meet all the other 
requirements to be included in PPAS for HIH.  
In the event of a local or national immunization program with a SARS -
CoV -2 or other vaccine,  participants who receive 1 or more doses of the 
vaccine listed above  at any time during the study will not be withdraw n 
from the study.  
9.4 Statistical Analyses   
The SAP core body will be finalized before the initiation of the study and may be amended, if 
necessary,  prior to database lock. It will i nclude a more technical and detailed description of the 
statistical analysis outlined in this section.  
9.4.1 General Considerations   
The statistical analysis will be conducted as follows:  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 51 of 84 • The study will be unblinded after all immunogenicity and safety data are collected for the 
follow -up period of 3  weeks after D22 (ie, 21 days after the last vaccination) (see 
Section  6.3.2  and Section  9.5). 
• The final database lock will occur after the 12 -month follow -up. 
No adjustment for multiplicity regarding multiple comparisons between study doses is planned in 
this study. Details will be provided in the SAP.  
 
9.4.2 Primary Endpoints   
Primary  Immunogenicity Objective:  
The immunogenicity parameters will be calculated with their 95% CIs using the exact binomial 
distribution (Clopper -Pearson method) for proportions and using normal approximation of log-
transformed for GMTs and GMTs ratio. The 95% CI of proportions difference (ie, difference 
between vaccine groups in seroconversion) will be calculated using Wilson Score method without 
continuity correction ( 19). All analyses will be conducted by study group and also by age stratum.  
 
The time windows used for collecting blood samples are: D01, D22 [+7], D43 [+7], D202 [+14], 
and D387 [+14]. To avoid redundancy and typing errors, these time windows will not be reported 
in all sections of this document.  
 
• Immunogenicity by HIH measurement method  
• GMTs of HAI Ab titers obtained on D22, and on D43 for comparison with D01, D202, 
and D387.  
• Geometric mean of individual ratios of HAI Ab titers D22/D01 and D43/D01; and 
D202/D01 and D387/D01.  
• Percent of participants with seroconversion defined as HAI Ab titer < 10 (1/dilution 
[1/dil]) on D01 and post -injection titer ≥ 40 (1/dil) on D22 or D43; or defined as HAI Ab 
titer ≥  10 (1/dil) on D01 and a ≥  4-fold increase in titer (1/dil) on D22 or D43.  
The interpretation of the results will account for seroconversion thresholds reported in 
FDA guideline  (18) for participants 18  – 64 years and ≥  65 years of age.  
• Percent of participants with HAI Ab titers ≥ 40 (1/dil) on D22, and percent of participants 
with HAI Ab titers ≥ 40 (1/dil) on D43. The same s tatistic will be calculated for D01, 
D202, and D387.  
The interpretation of the results will account for seroconversion thresholds reported in 
FDA guideline ( 18) for participants 18  – 64 years and ≥ 65 years of age.  
• Percent of participants with detectable HAI Ab titer with a titer ≥ 10 (1/dil) on D01, D22, 
D43, D202, and D387.  
• Difference and its 95% CI in seroconversion between the 3 study doses (Group 1 - Group 
3; Group 2 - Group 3, and Group 2 - Group 1) at D22 and D43.  
• Ratio of GMTs and its 95% CI for: Group1/Group3, Group2/Group3, and 
Group2/Group1 at D22, and at D43.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 52 of 84 • The RCDCs of pre -vaccinat ion titer prior to the first vaccination (D01), and post -
vaccination titer at D22, D43, D202, and D387 will be generated for each study dose. 
The RCDCs will include the plots of the 3 doses on the same figure.  
 
• Immunogenicity by SN measurement method  
• GMTs of NT Ab titer obtained on D22, and on D43 for comparison with D01, D202, and 
D387.  
• Geometric mean of individual ratios of NT Ab titer for D22/D01, D43/D01, D202/D01, 
and D387/D01.  
• Percentage of participants with NT Ab titers ≥ 20 (1/dil), ≥ 40 (1/dil), ≥  80 (1/dil) on 
D22, and on D43; compared to D01, D202, and D387.  
• Percent of participants with fold increase in NT Ab titer [post -vaccination/ pre -
vaccination] ≥  2 and ≥  4 on D22 and D43.  
• Percent of participants with detectable NT Ab titer ≥ 10 (1/dil) on D01, D22, D43, D202, 
and D387.  
• Difference and its 95% CI in percent of participants with  fold increase between the 3 
study doses (Group 1 - Group 3, Group 2 - Group 3, and Group 2 - Group 1) on D22, and 
on D43.  
• Ratio of GMs and its 95% CI for: Group1/Group 3, Group2/Group3, and Group2/Group1 
on D22, and on D43.  
• The RCDCs of pre -vaccination titer prior to the first vaccination (D01) and post -
vaccination titer at D22, D43, D202, and D387 will be generated for each study dose. 
The RCDCs will include the plots o f the three doses on the same figure.  
For each immunogenicity measurement method, the analysis will be conducted for each 
immunogenicity variable on the PPAS and on FAS.  
9.4.3 Secondary Endpoints   
Safety Objective:  
For the main safety parameters, 95% CIs of point estimates will be calculated using exact 
binomial method (Clopper -Pearson method) for single proportions and using the normal 
approximation for quantitative data.  
All analyses will be descriptive; no hypotheses will be tested.  
The number of participants with documented safety will be used as denominator of the 
frequencies.  
• For solicited reactions, the denominator will be the total number of participants who have non -
missing data for the endpoint considered  
• For unsolicited AEs, the denominator will be the total number of participants who were 
vaccinated with  the dose analyzed  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 53 of 84 Solicited reactions  
Solicited  reactions will be presented according to their nature (Medical Dictionary for  Regulatory 
Activities [MedDRA , the latest version at database lock ] preferred term [PT]) , intensity (Grade 1, 
2, or 3), time to onset, and number of days of occurrence . 
Unsolicited AEs  
Unsolicited AEs included in the analysis will be summarized in the saf ety overview and analyzed 
according to their nature (MedDRA  [the latest version at database lock ] system organ class [SOC] 
and PT classification) and relationship to the vaccination.  
Injection Site Reactions  
For each dose, the number and percentage of part icipants experiencing any injection site reaction 
after injection will be calculated.  
The description of injection site reactions will be presented according to:  
• Solicited injection site reactions  
All solicited injection site reactions that occur each day within 7 days after injection will be 
summarized and presented.  
• Unsolicited injection site reactions  
All unsolicited injection site reactions after vaccination, reported within 21  days after each 
vaccination will be described according to the type of events.  
Systemic Events and Reactions  
For each dose, the number and percentage of participants experiencing any unsolicited immediate 
systemic event in the 30  minutes after injection w ill be calculated.  
In addition, the description of systemic events will be structured according to:  
• Solicited systemic reactions  
All solicited systemic reactions that occur each day within 7 days after injection will be 
analyzed  
• Unsolicited systemic events  
All unsolicited systemic events reported after vaccination within 21 days after each 
vaccination will be described according to the type of events.  
Medically Attended Adverse Events  
MAAE safety summaries will be reported for within 21  days after each vacc ination, from D01 to 
D42, from D43 to D202, from D203 to D387, and overall study.  
Adverse Events of Special Interest  
The number and percentage of participants with AESIs reported after vaccination, within 21 days 
after each vaccination, and throughout the study will be calculated by outcome and seriousness.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 54 of 84 Serious Adverse Events  
The number and percentage of participants with SAEs reported after vaccination, within 21 days 
after each vaccination, will be calculated by outcome, seriousness, and relationship to the dose 
administered.  
The SafAS will be used for the safety analysis.  
9.4.4 Other Analysis   
The impact of the regional or national emergency declared by a governmental agency  on stu dy 
conduct will be summarized (eg, study discontinuation or discontinuation/delay/omission of the 
intervention due to the emergency). Any additional analyses and methods required to evaluate the 
impact on immunogenicity (eg, missing data due to the emergen cy) and safety will be detailed in 
the SAP.  
For a regional or national emergency declared by a governmental agency, contingency measures 
are included in Appendix 10.5: Contingency Measures for a regional or national emergency that is 
declared by a governmental agency.  
9.5 Interim Analyses   
The blind will be broken at the participa nt level after collecting all immunogenicity and safety 
data up to 21 days after last vaccination, data are cleaned, and database is locked. The study 
participants and the laboratory personnel who analyze the blood samples  will remain blinded 
throughout th e study. The study team will strive not to communicate the study unblinded data to 
the sites in order to minimize the bias in collecting the follow -up safety data.  
The main analysis of immunogenicity (HIH and SN measurement methods) data and safety will 
include all data up to 21 days after the last vaccination. The results of this analysis will help in 
selecting the  dose formulation for further clinical development. The results of this main  analysis 
may be reported in an interim clinical study report (CSR).  
A final database lock will occur after all data, including up to the 12 -month follow -up period, are 
collected. A final CSR would include the analysis of the safety and immunogenicity data at 6 - and 
12-month after the last vaccination to assess the persist ence of the antibody levels.  
No statistical adjustment is necessary because no hypothesis will be tested. Unblinded early looks 
at the safety data may take place to assess safety.  
 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 55 of 84 10 Supporting Documentation and Operational Considerations   
10.1 Appendix: Regulatory, Ethical, and Study Oversight Considerations   
Note: The term “par ticipant” is used throughout this protocol. However, the term “subject” will be 
used in the CRF in order to comply with the Clinical Data Interchange Standards Consortium 
(CDISC) requirements.  
10.1.1  Regulatory and Ethical Considerations   
• This study will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council f or International Organizations of Medical Sciences 
(CIOMS) international ethical guidelines  
• Applicable ICH Good Clinical Practice (GCP) guidelines  
• Applicable laws and regulations (eg, data protection law as General Data Protection 
Regulation [GDPR])  
• The pr otocol, ICF, IB, and other relevant documents (eg, advertisements) must be submitted to 
an IRB/IEC by the investigator or the Sponsor (according to local regulations) and reviewed 
and approved by the IRB/IEC before the study is initiated  
• Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants  
• Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study participants  
• The investigator or the Sponsor (according to local regulations)  will be responsible for the 
following:  
• Providing written summ aries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/IEC  
• Determining whether an incidental finding (as per Sanofi policy) should be returned to a 
participant and, if it meets the appropriate criteria, to ensure the finding is returned (an 
incidental finding is a previously undiagnosed medical condition that is discovered 
unintentionally and is unrelated to the aims of the study for which the tests are  being 
performed). The following should be considered when determining the return of an 
incidental finding:  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 56 of 84 • The return of such information to the study participant (and/or his/her designated 
healthcare professional, if so designated by the participant) is consistent with all 
applicable national, state, or regional laws and regulations in the country where the 
study is being conducted, and  
• The finding reveals a substantial risk of a serious health condition or has 
reproductive importance, AND has analytical validity, AND has clinical validity.  
• The participant in a clinical study has the right to opt out of being notified by the 
investigator of such incidental findings. In the event that the participant has opted 
out of being notified and the finding has conse quences for other individuals, eg, the 
finding relates to a communicable disease, investigators should seek independent 
ethical advice before determining next steps.  
• In case the participant has decided to opt out, the investigator must record in the site 
medical files that she/he does not want to know about such findings.  
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures  
• Providing oversight of the conduct of the study at the site and adherence to requirements 
of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical 
studies (if applicable), European Medical Device Regulation 2017/745 for clinical device 
research (if applicable), and all other applicable local regulations  
As applicable, according to Directive 2001/20/EC, the Sponsor will be responsible for obtaining 
approval from the Competent Authorities of the EU Member States and /or Ethics Committees, as 
appropriate, for any amendments to the clinical trial that are deemed as “substantial” (ie , changes 
which are likely to have a significant impact on the safety or physical or mental integrity of the 
clinical trial participants or on the scientific value of the trial) prior to their implementation.  
10.1.2  Financial Disclosure   
Information related to financial disclosure is described in the investigator’s contract.  
10.1.3  Informed Consent Process   
• The investigator or his/her representative will explain the nature of the study, including the 
risks and benefits, to the participants and answer all questions regarding the study, including 
what happens to the participant when his/her participatio n ends (post -trial access strategy for 
the study).  
• Participants must be informed that their participation is voluntary. Participants  will be required 
to sign a statement of informed consent that meets the requirements of 21 CFR 50, local 
regulations, ICH g uidelines, privacy and data protection requirements including those of the 
General Data Protection Regulation (GDPR) and of the French law, where applicable, and the 
IRB/IEC or study center.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 57 of 84 • The medical record must include a statement that written informed  consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. 
The authorized person obtaining the informed consent must also sign the ICF.  
• The actual ICF used at each center may differ, depending on l ocal regulations and IEC / IRB 
requirements. However, all versions must contain the standard information found in the 
sample ICF provided by the Sponsor. Any change to the content of the ICF must be approved 
by the Sponsor and the IEC / IRB prior to the fo rm being used.  
• If new information becomes available that may be relevant to the participant’s willingness to 
continue participation in the study, this will be communicated to him / her in a timely manner. 
Such information will be provided via a revised ICF  or an addendum to the original ICF.  
• Participants must be re -consented to the most current version of the ICF during their 
participation in the study. Where participants are not in the study anymore, the Sponsor must 
define if those participants must or no t re-consent or be informed of the revision (eg, if the 
processing of personal data is modified, if the Sponsor changes).  
• A copy of the ICF must be provided to the participant.  
The ICF will contain a specific section that addresses the use of remaining man datory samples for 
optional exploratory research, unless prohibited by local laws or IRBs/IECs . The investigator or 
designee will explain to each participant the objectives of the exploratory research. Participants 
will be told that they are free to refuse  to participate and may withdraw their consent at any time 
and for any reason during the storage period.  
Recruitment Procedures  
Before the start of the study, the investigator or designee  will contact an appropriate pool of 
potential participants and invit e them to participate in the study. The site will ensure that any 
advertisements used to recruit participants (eg, letters, pamphlets, posters) are submitted to Sanofi 
Pasteur prior to submission to the IEC / IRB for approval.  
For a regional or national em ergency declared by a governmental agency, contingency procedures 
may be implemented for the duration of the emergency. The participant should be verbally 
informed prior to initiating any changes that are to be implemented for the duration of the 
emergency  (eg. study visit delays/treatment extension).  
For a regional or national emergency declared by a governmental agency, contingency measures 
are included in Appendix 10.5: Contingency Measures for a regional or national emergency that is 
declared by a governmental agency.  
10.1.4  Data Protection   
All personal data collected and/or processed in relation to this study will be handled in compliance 
with all applicable Privacy & Data Protection laws and regulations, including the GDPR (General 
Data Protection Regulation). The study Sponsor is the Sanofi company responsible for ensuring 
compliance with this matter, when processing data from any individual who may be included in 
the Sanofi databases, including investigators, nurses, experts, service providers, Ethics Committee 
members, etc.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 58 of 84 When archiving or processing personal data pertai ning to the investigator and/or to the 
participants, the Sponsor shall take all appropriate measures to safeguard and prevent access to 
this data by any unauthorized third party.  
Protection of participant personal data  
Data collected must be adequate, rele vant and not excessive, in relation to the purposes for which 
they are collected. Each category of data must be properly justified and in line with the study 
objective.  
• Participants’ race and ethnicity will be collected in this study because these data are  required 
by regulatory agencies ( 20). 
• Participants will be assigned a unique identifier by the Sponsor. Any participant records or 
datasets t hat are transferred to the Sponsor or its service providers will be identifiable only by 
the unique identifier; participant names or any information which would make the participant 
identifiable will not be transferred to the Sponsor.  
• The participant must be informed that his/her personal study -related data will be used by the 
Sponsor in accordance with applicable data protection laws. The level of disclosure must also 
be explained to the participant as described in the informed consent.  
• The participant mus t be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities.  
• Participants must be informed that their study -related data will be used for the whole “product 
development program”, ie, for this study as well as for the following steps necessary for the 
development of the investigational product, including to support n egotiations with payers and 
publication of results.  
Protection of data related to professionals involved in the study  
• Personal data (eg, contact details, affiliation(s) details, job title and related professional 
information, role in the study, professiona l resume, training records) are necessary to allow 
Sanofi to manage involvement in the study and/or the related contractual or pre -contractual 
relationship. They may be communicated to any company of the Sanofi group (“Sanofi”) or to 
Sanofi service provide rs, where needed.  
• Personal data can be processed for other studies and projects. At any time, objection to 
processing can be made by contacting the Sanofi Data Protection Officer (link available at 
Sanofi.com).  
• In case of refusal to the processing of perso nal data by or on behalf of Sanofi, it will be 
impossible to involve the professionals in any Sanofi study. In case the professionals have 
already been involved in a Sanofi study, they will not be able to object to the processing of 
their personal data as long as they are required to be processed by applicable regulations. The 
same rule applies in case the professionals are listed on a regulatory agency’s disqualification 
list. 
• Personal data can be communicated to the following recipients:  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 59 of 84 • Personnel within Sanofi or partners or service providers involved in the study  
• Judicial, administrative and regulatory authorities, in order to comply with legal or 
regulatory requirements and/or to respond to specific requests or orders in the 
framework of judicial or adm inistrative procedures. Contact details and identity may 
also be published on public websites in the interest of scientific research transparency  
• Personal data may be transferred towards entities located outside the Economic European 
Area, in countries whe re the legislation does not necessarily offer the same level of data 
protection or in countries not recognized by the European Commission as offering an adequate 
level of protection. Those transfers are safeguarded by Sanofi in accordance with the 
requirem ent of European law including, notably:  
• The standard contractual clauses of the European Commission for transfers towards 
our partners and service providers,  
• Sanofi’s Binding Corporate Rules for intra -group transfers.  
• Professionals have the possibility to lodge a complaint with Sanofi leading Supervisory 
Authority, the “Commission Nationale de l’Informatique et des Libertés” (CNIL) or with any 
competent local regulatory authority.  
• Personal data of professionals will be retained by Sanofi for up to thirty (3 0) years, unless 
further retention is required by applicable regulations.  
• In order to facilitate the maintenance of investigators personal data, especially if they 
contribute to studies sponsored by several pharmaceuticals companies, Sanofi participates in  
the Shared Investigator Platform (SIP) and in the Transcelerate Investigator Registry project 
(https://transceleratebiopharmainc.com/initiatives/investigator -registry/). Therefore, personal 
data will be securely shared by Sanofi with other pharmaceutical company members of the 
Transcelerate project. This sharing allows investigators to keep their data up -to-date once for 
all across pharmaceutical companies participating in the project, with the right to object to the 
transfer of the data to the Transcelera te project.  
• Professionals have the right to object to the processing, to request for access to and the 
rectification of their personal data, as well as their erasure (where applicable) by contacting 
the Sanofi Data Protection Officer: Sanofi DPO - 54 rue L a Boétie - 75008 PARIS - France (to 
contact Sanofi by email, visit https://www.sanofi.com/en/our -responsibility/sanofi -global -
privacy -policy/contact).  
10.1.5  Committees Structure   
Partic ipant safety will be continuously monitored by the Sponsor’s internal safety review 
committee which includes safety signal detection at any time during the study. The Sponsor’s 
internal safety review committee, led by the PV representative and the RMO and designee(s),  will 
be responsible for the blinded review, assessment, and evaluation of safety data generated from 
this study up to the D43 data unblinding for the main analysis. This committee is empowered to 
recommend a pause in recruitment and/or further  vaccination while it investigates any potential 
signal or concern.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 60 of 84 This study will not include an early safety data review.  
10.1.6  Dissemination of Clinical Study Data   
Study participants  
At the end of the clinical study, the Sponsor may publish the study results in scientific journal(s). 
As part of the review for publication, independent scientists may need to use “coded” data of all 
the study participants to independently ver ify the study’s results.  
Sanofi shares information about clinical trials and results on publicly accessible websites, based 
on company commitments, international and local legal and regulatory requirements, and other 
clinical trial disclosure commitments e stablished by pharmaceutical industry associations.   These 
websites include clinicaltrials.gov, EU clinicaltrialregister (eu.ctr), and sanofi.com, as well as 
some national registries.  
In addition, results from clinical trials in patients are required to be  submitted to peer -reviewed 
journals following internal company review for accuracy, fair balance, and intellectual property. 
For those journals that request sharing of the analyzable data sets that are reported in the 
publication, interested researchers a re directed to submit their request to 
clinicalstudydatarequest.com.  
Individual participant data and supporting clinical documents are available for request at 
clinicalstudydatarequest.com. While making information available we continue to protect the 
privacy of participants in our clinical trials. Details on data sharing criteria and process for 
requesting access can be found at this web address: clinicalstudydatarequest.com.  
Professionals involved in the study or in the drug development program  
Sanofi may  publicly disclose, and communicate to relevant authorities/institutions, the funding, 
including payments and transfers of value, direct or indirect, made to healthcare organizations and 
professionals and/or any direct or indirect advantages and/or any rel ated information or document 
if required by applicable law, by regulation or by a code of conduct such as the “EFPIA Code on 
Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and 
Healthcare Organizations”.  
 
10.1.7  Data Quality Assurance   
• All participant data relating to the study will be recorded on electronic CRFs unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data ). The investigator is 
responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the CRF.  
• Guidance on completion of CRFs will be provided in the CRF Completion Instructions . 
• The investigator must permit st udy-related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 61 of 84 • Quality tolerance limits (QTLs) will be predefined to identify systematic issues that can 
impact  patient safety and/or rel iability of study results. These predefined parameters will be 
monitored during the study, and important deviations from the QTLs and remedial actions 
taken will be summarized in the clinical study report.  
• Monitoring details describing strategy including d efinition of study critical data items and 
processes (eg, risk -based initiatives in operations and quality such as risk management and 
mitigation strategies and analytical risk -based monitoring), methods, responsibilities and 
requirements, including handli ng of noncompliance issues and monitoring techniques (central, 
remote, or on -site monitoring) are provided in the monitoring plan.  
• The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.  
• The Spon sor assumes accountability for actions delegated to other individuals (eg, contract 
research organizations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by the investigator for 25 years after the s ignature of the final study report unless 
local regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the Sponsor. No records 
may be transferred to a nother location or party without written notification to the Sponsor.  
• The protocol will be signed by the RMO, and a Protocol Investigator Agreement Form (PIAF) 
will be signed by all investigators. The clinical study report will be signed by the RMO and 
the coordinating investigator. In case no coordinating investigator has been designated, it will 
be the responsibility of the RMO or designee(s) to identify the signatory investigator.  
10.1.8  Source Documents   
“Source data” are the data contained in source documents. Source documents are original 
documents or certified copies, and include, but are not limited to, DCs, medical and hospital 
records, screening logs, informed consent forms, tele phone contact logs, and worksheets.  
• Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.  
• Data entered in the CRF that are transcr ibed from source documents must be consistent with 
the source documents or the discrepancies must be explained. The investigator may need to 
request previous medical records or transfer records, depending on the study. Also, current 
medical records must be  available.  
• The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
• Study monitors will perform ongoing source data verification to confirm that data entered into 
the CRF by authorized site pers onnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH  GCP, and all applicable regulatory requirements.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 62 of 84 10.1.9  Study and Site Start and Closure   
Study personnel will be informed of which clinical supplies will be provided by the Sponsor or 
the site.  
The study start date is considered the date of the first visit planned in the SoA of the first 
participant.  
The Sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretio n of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been either destroyed or returned to the Sponsor, all samples are shipped to the appropriate 
laborator ies, the center study -site has all the documents necessary for archiving and a study -site 
closure visit has been performed along with a site close out form  submitted to the IRB, as 
required.  
The investigator may initiate study -site closure at any time, pro vided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the Sponsor or investigator may include but are not 
limited to:  
For study termination:  
• Discontinuation o f further study intervention development  
• Information on the study intervention leads to doubt as to the benefit/risk ratio  
For site termination:  
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health author ities, the Sponsor’s procedures, or GCP guidelines  
• Inadequate or no recruitment (evaluated after a reasonable amount of time) of participants by 
the investigator  
• Total number of participants included earlier than expected  
 
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by the applicable  
regulatory requirements. The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow -up. 
10.1.10  Publication Policy   
Informatio n related to publication policy is described in the investigator’s contract.  
 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 63 of 84 10.2 Appendix: Clinical Laboratory Tests   
• The tests detailed in Table 10.1 will be performed at the study site.  
• Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section  5 of the protocol.  
• Additional tests may be performed at any time during the study as determined necessary by 
the investigator or required by local regulations.  
Table 10.1 - Protocol -required safety laboratory tests   
Laboratory 
Tests  Time period 
for assessment  Parameters  
Pregnancy 
testing  before each 
vaccination  • Highly sensitive [serum or urine] human chorionic gonadotropin 
(hCG) pregnancy test (as needed for women of childbearing 
potential)*  
* Local urine testing will be standard for the protocol unless serum testing is required by local regulation 
or IRB/IEC.  
 
Investigators must document their review of each laboratory safety report.  
  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 64 of 84 10.3 Appendix: AEs and SAEs: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting   
10.3.1  Definition of AE   
AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the study 
intervention.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or dis ease (new or exacerbated) temporally 
associated with the use of study intervention.  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments (eg, ECG, radiological scans, vital signs measurements), including those 
that worsen from baseline, considered clinically significant in the medical and scientific 
judgment of the investigator (ie, not related to progression of underlying disease).  
• Exacerbation of a chronic or i ntermittent pre -existing condition including either an increase 
in frequency and/or intensity of the condition.  
• New condition detected or diagnosed after study intervention administration even though it 
may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected intervention -intervention 
interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported  as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.  
 
Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.  
• Medical or surg ical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 65 of 84 • Anticipated day -to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
 
Other Definitions  
Adverse Reaction:  
An adverse reaction (AR) is any noxious and unintended response to a study intervention 
related to any dose.  
Immediate Event/Reaction:  
Immediate events are recorded to capture medically relevant unsolicited systemic AEs which 
occur within the first 30 minutes after vaccination.  
Reactogenicity / Solicited Reactions:  
The reactogenicity  of a vaccine refers to the pr operty of such vaccine to be able to produce 
common "expected" adverse reactions (either systemic or at the injection site) and its associated 
signs and symptoms.  
A solicited reaction is an “expected” adverse reaction (sign or symptom) observed and reporte d 
under the conditions (nature and onset) pre -listed in the protocol and CRF (eg, injection site 
pain or headache occurring between the day of vaccination and the next 7 days).  
By definition, solicited  reactions are considered as being related to the corresponding IMP 
administered.  
For injectable vaccines, solicited reactions can either be solicited injection/administration site 
reactions or solicited systemic reactions  
Injection / Administration Site R eactions:  
An injection/administration site reaction is an AR at and around the injection/administration site 
of the IMP. Injection/administration site reactions are commonly inflammatory reactions.  
Solicited injection  / administration site reactions are re actions at and around the 
injection  / administration site of the IMP observed and reported under the conditions (nature 
and onset) pre -listed in the protocol and CRF. It is considered by default as being related to the 
IMP administered at that site.  
Note: “Administration site reaction” term is only to be used for vaccines that are not intended to 
be administered by injection.  
Systemic AR:  
Systemic ARs are all ARs that are not injection or administration site reactions. They therefore 
include systemic manife stations such as headache, fever, as well as localized or topical 
manifestations that are not associated with the injection or administration site (eg, erythema that 
is localized but that is not occurring at the injection site).  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 66 of 84 Solicited systemic reaction s are systemic AEs observed and reported under the conditions 
(nature and onset) pre -listed in the protocol and CRF. Solicited systemic reactions occurring 
during the specified collection period are always considered related to the IMP even if there is 
evidence of alternative etiology.  
Unsolicited AE/AR:  
An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions, 
ie, pre -listed in the CRF in terms of diagnosis and onset window post -vaccination. For example, 
varicella or a solicited term such as headache starting after the solicited observation period (eg, 
headache starting on Day  10 post -vaccination in the case where headache occurring between the 
day of vaccination and the next 7 days is pre -listed in the protocol and CR F as a solicited 
reaction).  
An unsolicited AR  is an unsolicited AE that is considered related to an IMP.  
Unsolicited AEs includes both serious (SAEs) and non -serious unsolicited AEs.  
All unsolicited AEs occurring at and around the IMP injection/administrat ion site are to be 
considered by default as related to the IMP administered at that site  and are therefore referred as 
unsolicited injection/administration site ARs . 
All unsolicited AEs which are not at and around the IMP injection/administration site, are  
referred as systemic unsolicited AE. For each unsolicited systemic AE, the investigator assesses 
the relationship to the IMP. Systemic AEs assessed as related to IMP are referred as systemic 
ARs.  
Adverse Event of Special Interest (AESI):  
An AESI (serious or non -serious) is one of scientific and medical concern specific to the 
Sponsor’s study intervention or program, for which ongoing monitoring and rapid 
communication by the investigator to the Sponsor can be appropriate. Such an event might 
warra nt further investigation in order to characterize and understand it. Depending on the nature 
of the event, rapid communication by the study Sponsor to other parties (eg, regulators) might 
also be warranted.  
Medically Attended AE (MAAE):  
An MAAE is a new on set or a worsening of a condition that prompts the participant to seek 
unplanned medical advice at a physician’s office or Emergency Department. Physician contact 
made over the phone or by e -mail will be considered a physician office visit for the purpose of 
MAAE collection. This includes medical advice seeking during the study visit or routine 
medical care. This definition excludes follow -up visits of chronic conditions with an onset prior 
to entry in the study, and solicited reactions.  
10.3.2  Definition of SAE   
An SAE is defined as any adverse event that, at any dose:  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 67 of 84 a. Results in death  
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires inpatient hospitalization or prolongation of existing hospitalization  
• In gen eral, hospitalization signifies that the participant has been admitted (usually involving 
at least an overnight stay) at the hospital or emergency ward for observation and/or 
treatment that would not have been appropriate in the physician’s office or outpa tient 
setting. Complications that occur during hospitalization are AEs. If a complication prolongs 
hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to 
whether hospitalization occurred or was necessary, the AE s hould be considered serious.  
• Hospitalization for elective treatment of a pre -existing condition that did not worsen from 
baseline is not considered an AE.  
d. Results in persistent or significant disability/incapacity  
• The term disability means a substantial d isruption of a person’s ability to conduct normal 
life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
accidental trauma ( eg, sprained ankle) that may interfere with or prevent everyday life 
functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Is other medically important event  
• The term "Other medically important events" refers to events which do not meet any of the 
above seriousness criteria, but which are considered as serious based on investigator 
medical judgment.  
• Medical or scientific judgment should be exercised by the investigator in deciding whether 
expedited reporting is ap propriate in other situations such as significant medical events that 
may jeopardize the health of the participant or may require intervention to prevent one of 
the other outcomes listed in the above definition. These important medical events should 
also u sually be considered serious.  
• Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias, convulsions, or 
development of intervention dependency or interven tion abuse, new-onset diabetes or 
autoimmune disease, or suspected transmission of any infectious agent via an authorized 
medicinal product . 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 68 of 84 Note:  Serious  and severe  are not synonymous. The term severe  is often used to describe the 
intensity of a specific event as corresponding to Grade 3. This is not the same as serious,  which is 
based on participant / event outcome or action criteria usually associated with events that pose a 
threat to a participant’s  life or functioning.  
10.3.3  Recording and Follow -Up of AE and/or SAE   
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospital progress notes, laboratory reports, and diagnostics reports) 
related to the event.  
• The investigator will then record all relevant AE/SAE information.  
• It is not acceptable for the investigator to send photocopies of the participa nt’s medical 
records to the Sponsor  in lieu of completion of the CRF pages.  
• There may be instances when copies of medical records for certain cases are requested by 
the Sponsor. In this case, all participant identifiers, with the exception of the participa nt 
number, will be redacted on the copies of the medical records before submission to the 
Sponsor.  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the diagn osis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
 
Assessment of Causal Relationship  
By convention, all AEs reported at the injection site (either solicited or unsolicited) and all 
solicited systemic AEs are considered to be rela ted to the IMP (see definition in Section  6) and 
therefore are referred to as reactions and do not require the inve stigator’s opinion on 
relatedness.  
• Causal relationship of unsolicited systemic AEs and SAEs will be recorded as follows:  
• For non -serious unsolicited systemic AEs (except for non -serious AESIs), relationship 
to study intervention will usually be assessed by the investigator only.  
• For SAEs and non -serious AESIs, relationship to study intervention will be assessed 
by both the investigator and the Sponsor (except for injection site reactions which will 
be related by default). Sponsor assessment is entered in the GPV database only.  
• For SAEs only, the causal relationship to study procedures (related/not related to study 
procedure s) will be assessed by both the investigator and the Sponsor. Sponsor 
assessment is entered in the GPV database only.  
• The investigator will assess the causal relationship  between each unsolicited systemic AE 
and the study intervention administered as eithe r not related  or related , based on the 
following definitions:  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 69 of 84 • Not related – The AE is clearly / most probably caused by other etiologies such as 
participants’ underlying condition, therapeutic intervention, or concomitant therapy; or 
the delay between vacc ination and the onset of the AE is incompatible with a causal 
relationship; or the AE started before the first vaccination (screening phase, if 
applicable)  
• Related – There is a “reasonable possibility” that the AE was caused by the study 
intervention admin istered, meaning that there are facts (evidence) or arguments to 
suggest a causal relationship  
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk  
factors, as well as the temporal relationship of the event to study intervention administration 
will be considered and investigated.  
• The investigator will also consult the IB and/or Product Information, for marketed products, 
in his/her assessment.  
• For ea ch AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causal relationship.  
• There may be situations in which an SAE has occurred and the investigator has minimal 
information to i nclude in the initial report to the Sponsor. However, it is very important that 
the investigator always makes an assessment of causal relationship for every event before 
the initial transmission of the SAE data to the Sponsor.  
• The investigator may change h is/her opinion of causal relationship in light of follow -up 
information and send an SAE follow -up report with the updated causal relationship 
assessment.  
• The causal relationship assessment is one of the criteria used when determining regulatory 
reporting r equirements.  
 
Follow -up of AEs and SAEs  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the Sponsor to 
elucidate the nature and/or causal relationship of the AE or SAE as fully as possible. This 
may include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.  
• If a participant dies during participation in the stud y or during a recognized follow -up 
period, when available the investigator will provide the Sponsor with a copy of any 
post-mortem findings including histopathology.  
• New or updated information will be recorded in the originally submitted documents.  
• The inv estigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 70 of 84 • Serious adverse events likely to be related to the study intervention, that persist at the end of 
the study will be followed up by the investigator unt il their complete disappearance or the 
stabilization of the participant’s condition. The investigator will inform the Sponsor of the 
date of final disappearance of the event or the date of “chronicity” establishment.  
10.3.4  Reporting of SAEs   
SAE Reporting to the Sponsor  via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to the Sponsor will be the electronic data 
collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data collection 
tool (see next section) to report the event within 24 hours. The site will enter the SAE data 
into the electronic system as soon as it becomes available.  
• After the study is completed at a  given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated data on 
a previously reported SAE af ter the electronic data collection tool has been taken off -line, 
then the site can report this information on a paper SAE form (see next section).  
 
SAE Reporting to the Sponsor  via Paper CRF  
• The SAE paper CRF can be sent to the Sponsor by one of  the foll owing means:  
• By fax, to the following number: 1 -570-957-2782  
• In PDF format to the following e -mail address, using a method of transmission that 
includes password protection:  
PV.outsourcing@sanofi.com  or USPVmailbox@sanofi.com  
• By express mail, to the following address:  
Sanofi GPV mail room  
55 Corporate Drive  
Bridgewater, New Jersey 08807  
 
Safety Emergency Call  
If, as per the investigator’s judgment, a participant experiences a medical emergency, the 
investigator may contact the Sponsor's RMO for advi ce on how to address any study -related 
medical question or problem. If the RMO is not available, then the investigator may contact the 
Call Center —available 24  hours a day, 7  days a week —that will forward all safety emergency 
calls to the appropriate prima ry or back -up Sanofi Pasteur contact, as needed. The toll -free 
contact information for the Call Center will be provided separately.  
This process does not replace the need to report an SAE. The investigator is still required to 
follow the protocol -defined p rocess for reporting SAEs to the GPV Department.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 71 of 84 In case of emergency code -breaking, the investigator is required to follow the code -breaking 
procedures described in Section  6.3.2 . 
 
10.3.5  Assessment of Intensity   
The investigator will make an assessment of  intensity for each AE reported during the study. An 
intensity grade will be assigned to each AE. The intensity grading scales used in this study are 
adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and 
Adolescent Volun teers Enrolled in Preventive Vaccine Clinical Trials, September 2007”.  
10.3.5.1  Tables for Clinical Abnormalities   
10.3.5.1.1  Solicited AR Intensity Grading Scale   
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 72 of 84 Table 10.2 - Solicited injection site reactions: terminology, definitions, and intensity scales – Adults 18 years of age and older   
CRF term 
(MedDRA 
lowest level 
term [LLT])  Injection site pain  Injection site 
erythema  Injection site swelling  Injection site 
induration  Injection site 
ecchymosis  
eDiary term  Pain Redness  Swelling  Hardening  Bruising  
Definition  Pain either present spontaneously or 
when the injection site is touched or 
injected limb is mobilized  Presence of a redness 
including the 
approximate point of 
needle entry  Swelling at or near the 
injection si te 
Swelling or edema is 
caused by a fluid 
infiltration in tissue or 
cavity and, depending 
on the space available 
for the fluid to 
disperse, swelling may 
be either soft 
(typically) or firm 
(less typical) to touch 
and thus can be best 
described by looking 
at the size of the 
swelling  Hardening at or near the 
injection site.  
Hardening is caused by a 
slow diffusion of the 
product in the tissue 
leading to a thick or hard 
area to touch at or near 
the injection site and thus 
can be best described by 
looking at the size of the 
hardening.  Bruising is the result of the 
diffusion of blood in the 
skin from ruptured blood 
vessels that forms a purple 
or black and blue spot on 
the skin. It can be best 
described by looking at its 
size. 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 73 of 84 Intensity scale*  CRF:  
Grade  1: A type of adverse event that is 
usually transient and may require only 
minimal treatment or therapeutic 
intervention. The event does not 
generally interfere with usual activities 
of daily living.  
Grade  2: A type of adverse event that is 
usually alleviated with ad ditional 
therapeutic intervention. The event 
interferes with usual activities of daily 
living, causing discomfort but poses no 
significant or permanent risk of harm to 
the research participant.  
Grade  3: A type of adverse event that 
interrupts usual activit ies of daily living, 
or significantly affects clinical status, or 
may require intensive therapeutic 
intervention.  
 
eDiary:  
Grade 1: No interference with activity  
Grade 2: Some interference with activity  
Grade 3: Significant; prevents daily 
activity  Grade  1:  
≥ 25 to ≤  50 mm 
 
Grade  2:  
≥ 51 to ≤  100 mm 
 
Grade  3: > 100 mm Grade  1:  
≥ 25 to ≤  50 mm 
 
Grade  2:  
≥ 51 to ≤  100 mm 
 
Grade  3: > 100 mm Grade  1:  
≥ 25 to ≤  50 mm 
 
Grade  2:  
≥ 51 to ≤  100 mm 
 
Grade  3: > 100 mm Grade  1:  
≥ 25 to ≤  50 mm 
 
Grade  2:  
≥ 51 to ≤  100 mm 
 
Grade  3: > 100 mm 
* For pain, the scale will be provided in the CRF and the intensity will be registered in the eDiary. For other injection sit e reactions (erythema, swelling, induration, and ecchymosis), the 
classification as Grades 1, 2, or 3 will be applied at the time of statistical analysis; the scale is provided for information purposes only. The actual size of the reaction will be reported in the 
CRF.   
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 74 of 84 Table 10.3 - Solicited systemic r eactions: terminology, definitions, and intensity scales – Adults 18 years of age and older   
CRF term (MedDRA 
lowest level term [LLT])  Fever  Headache  Malaise  Myalgia  
eDiary term  Temperature  Headache  Feeling unwell  Muscle aches and pains  
Definition  Elevation of temperature to 
≥°38.0°C (≥  100.4°F)  Pain or discomfort in 
the head or scalp. 
Does not include 
migraine.  General ill feeling.  
Malaise is a generalized feeling of 
discomfort,  illness, or lack of well -
being that can be associated with a 
disease state. It can be accompanied 
by a sensation of exhaustion or 
inadequate energy to accomplish 
usual activities.  Muscle aches and pains are common and can 
involve more than one muscle at t he same time. 
Muscle pain can also involve the soft tissues that 
surround muscles. These structures, which are 
often referred to as connective tissues, include 
ligaments, tendons, and fascia (thick bands of 
tendons).  
Does not apply to muscle pain at the in jection site 
which should be reported as injection site pain.  
Intensity scale*  Grade  1: ≥ 38.0°C to ≤  38.4°C,  
or ≥ 100.4°F to ≤  101.1°F  Grade  1:  
CRF : A type of adverse event that is usually transient and may require only minimal treatment or therapeutic 
intervention. The event does not generally interfere with usual activities of daily living.  
eDiary : No interference with activity  
 Grade  2: ≥ 38.5°C to ≤  38.9°C,  
or ≥ 101.2°F to ≤  102.0°F  Grade  2:  
CRF : A type of adverse event that is usually alleviated with additional therapeutic intervention. The event 
interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of 
harm to the research participant.  
eDiary : Some interference with activity  
 Grade  3: ≥ 39.0°C  
or ≥ 102.1°F  Grade  3:  
CRF : A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, 
or may require intensive therapeutic intervention.  
eDiary : Significant; prevents daily activity  
* For all reactions (except fever), the scale will be provided in the CRF and the intensity will be registered in the eDiary. For f ever, the body temperature will be recorded, and the 
classification as Grade  1, 2, or 3 will be assigned at the time of the statist ical analysis based on the unit used to measure the temperature and the intensity scale.  
 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 75 of 84 Important notes for the accurate assessment of temperature:  
Participants are to measure body temperature once per day, preferably alw ays at the same time , 
and using the same standard unit of the considered country (Celsius or Fahrenheit) consistently . 
The optimal time for measurement is the evening, when body temperature is the highest. 
Temperature is also to be measured at the time of any apparent fever. The observed daily 
temperature and the route of measurement are to be recorded in the eDiary , and the highest 
temperature will be recorded by the site in the CRF. The preferred route for this study is oral.  
10.3.5.1.2  Serious and Non -serious Unsol icited AE Intensity Grading Scale   
For measurable unsolicited AEs that are part of the list of solicited reactions, the corresponding 
scale for solicited reactions will be used (s ee Section  10.3.5.1.1 ). 
All other unsolicited AEs, including SAEs, will be classified according to the following inten sity 
scale:  
• Grade 1  
• CRF: A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.  
• eDiary:  No interference with activity.  
• Grade 2  
• CRF: A type of adverse event that is usually alleviated with additional therapeutic 
intervention. The event interferes with usual activities of daily living, causing discomfort 
but poses no significant or permanent r isk of harm to the research participant.  
• eDiary:  Some interference with activity.  
• Grade 3  
• CRF: A type of adverse event that interrupts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic intervention.  
• eDiary:  Significant; prevents daily activity.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 76 of 84 10.4 Appendix: Contraceptive and Barrier Guidance   
10.4.1  Definitions   
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (see below).  
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a m enstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation should be considered.  
Women in the following categories are not considered WOCBP  
1) Premenarchal  
2) Premenopausal female with 1 of the following:  
• Documented hystere ctomy  
• Documented bilateral salpingectomy  
• Documented bilateral oophorectomy  
 
For individuals with permanent infertility due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.  
Note: Documentation can come from the site personnel’s: review of the participant’s medical 
records, medical examination, or medical history interview.  
3) Postmenopausal female  
• A postmenopausal state is defined as no men ses for 12 months without an alternative 
medical cause.  
• A high follicle stimulating hormone (FSH) level in the postmenopausal range may 
be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the absence of 
12 months of amenorrhea, confirmation with more than one FSH measurement is 
required.  
• Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non -estrogen hormonal highly effective contrac eption methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment.  
  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 77 of 84 10.4.2  Contraception Guidance   
• CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
• Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per year when used 
consistently and correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulation  
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion/ligation  
• Azoospermic partner (vasectomized or due to a medical cause)  
Azoospermia is a highly effective contraceptive method provided that the partner is the sole sexual partner of 
the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used.  
Note: documentation  of azoospermia for a male participant can come from the site personnel’s review of the 
participant’s medical records, medical examination, or medical history interview.  
• Highly Effective Methodsb That Are User Dependent Failure rate of <1% per year when u sed 
consistently and correctly.  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated with inhibition of 
ovulation  
− oral 
− intravaginal  
− transdermal  
− injectable  
• Progestogen -only hormone contraception associated with inhibition of ovulation  
− oral 
− injectable  
• Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of s exual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle 
of the participant.  
• Effective Methodsc That Are Not Considered Highly Effective Failure rate of ≥ 1% per year when used 
consistently and correctly.  
• Progestogen -only oral hormonal contraception where inhibition of ovulation is not the primary mode of 
action  
• Male or female condom with or without spermicide  
• Cervical cap, diaphragm, or sponge with spermicide  
• A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double -
barrier methods)  
a) Contraceptive use by men or women should be consistent with local regulations regarding the use of 
contraceptive methods for those participating in clinical studies.  
b) Failure rate of <1% per year when used consistently and correctly.  Typical use failure rates differ from those 
when used consistently and correctly.  
c) Considered effective, but not highly effective - failure rate of ≥  1% per year.  
Note: Periodic abstinence (c alendar, symptothermal, post -ovulation methods), withdrawal (coitus 
interruptus), spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of 
contraception.  
Male condom and female condom should not be used together (due to risk of failure from friction).  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 78 of 84 10.5 Appendix: Contingency measures for a regional or national emergency that is 
declared by a governmental agency   
Continuation of the study in the event o f a regional or national emergency declared by a 
governmental agency:  
A regional or national emergency declared by a governmental agency (eg, public health 
emergency, natural disaster, pandemic, terrorist attack) may prevent access to the clinical trial si te. 
Contingency procedures are suggested below and in Sections  5.5, 6.4, 7.1.1 , 8, 9.4.4 , and 10.1.3  
for an emergency that prevents access to the study site, to ensure the safety of the participants, to 
consider continuity of the clinical study conduct, protect study integrity, and assist in maintaining 
compliance with Good Clinical Practice in Conduct of Clinical Trials Guidance. Sponsor 
agreement MUST be obtained prior to the implementation of these procedures for the duration of 
the emergency.  
 
During  the emergency, if the site will be unable to adequately follow protocol mandated 
procedures, alternative treatment outside the clinical study should be proposed, and enrollment, 
randomization, administration of study intervention, and blood sampling may be temporarily 
delayed/halted (see also Section  5.5). 
Attempts should be made to perform all assessments in accordance with the approved protocol to 
the extent possible. In case this is not possible due to a temporary disruption caused by an 
emergency, focus should be given to assessme nts necessary to ensure the safety of participants 
and those important to preserving the main scientific value of the study.  
Procedures to be considered in the event of a regional or national emergency declared by a 
governmental agency:  
• If onsite visits a re not possible, remote visits (eg, with home nurses, home health vendor, etc.) 
may be planned for the blood collection and collection of possible safety data,  
• If onsite visits are not possible visit windows may be extended for assessment of safety and/or 
data that cannot be obtained remotely.  
Contingencies implemented due to emergency will be documented.  
10.6 Appendix: Risk -based Approach   
ICH E6 -R2 guideline for GCP is introducing the  « risk -based approach » concept which permits 
to focus efforts on what is critical for a study and most specifically on Critical Data and Critical 
Processes. Critical data and processes are defined for the study with associated risks in the Study 
Risk Man agement Plan.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 79 of 84 10.7 Appendix: Abbreviations   
1/dil  1/dilution  
Ab  antibody  
AE  adverse event  
AESI   adverse event of special interest  
AR  adverse reaction  
BARDA  Biomedical Advanced Res earch and Development Authority  
CBER   Center for Biologics Evaluation and Research  
CDISC Clinical Data Interchange Standards Consortium  
CFR   Code of Federal Regulation  
CI  confidence interval  
CIOMS  Council for International Organizations of Medical Sciences  
CNIL   Commission Nationale de l’Informatique et des Libertés  
COVID -19 Coronavirus Disease 2019  
CRB   case report book  
CRF   case report form  
CSR   clinical study report  
D  day 
DNA   deoxyribonucleic acid  
ECG   Electrocardiogram  
eDiary   electronic diary  
ELISA   enzyme -linked immunosorbent assay  
FAS  full analysis set  
FDA   Food and Drug Administration  
FSH  Follicle stimulating hormone  
GCP   Good Clinical Practice  
GDPR   General Data Protection Regulation  
GLA/SE  Glucopyranosyl Lipid A in stable oil -in-water e mulsion  
GMT   geometric mean titer  
GPV   Global Pharmacovigilance  
HA  hemagglutinin  
HAI  hemagglutination inhibition  
HCG   human chorionic gonadotropin  
HIH  hemagglutination inhibition using horse red blood cells  
HIPAA  Health Insurance Portability and Account ability Act  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 80 of 84 HRBC   horse red blood cells  
HRT   Hormonal replacement therapy  
IB  Investigator’s Brochure  
ICF  informed consent form  
ICH  International Council for Harmonisation  
IEC  Independent Ethics Committees  
IM  intramuscular  
IMP  Investigational Medicina l Product  
IRB  Institutional Review Boards  
IRT  interactive response technology  
LLT  lowest level term  
MAAE   medically attended adverse event  
MDCK  Madin -Darby canine kidney  
MedDRA  Medical Dictionary for Regulatory Activities  
NA  neuraminidase  
NIMP   Non- Investigational Medicinal Product  
NT  Neutralization  
PPAS   Per-protocol analysis set  
PSC  Protein Sciences Corporation  
PT  preferred term  
PV  pharmacovigilance  
QTL   quality tolerance limits  
RCDC   reverse cumulative distribution curve  
rHA  recombinant hemagglutinin  
RMO   Responsible Medical Officer  
RNA   ribonucleic acid  
SAE   Serious adverse events  
SafAS   Safety Analysis Set  
SAP  Statistical analysis plan  
SARS -COV -2 severe acute respiratory syndrome coronavirus 2  
SE  stable emulsion  
SIP  Shared Investigat or Platform  
SN  seroneutralization  
SoA  Schedule of Activities  
SOC   system organ class  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 81 of 84 SUSAR  suspected unexpected serious adverse reactions  
TBD   to be determined  
V  visit 
WOCBP  Woman of Childbearing Potential  
 
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 82 of 84 11 References   
1. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and 
control of influenza with vaccines: recommendations of the Advisory Committee on 
Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR -8):1-62. 
2. Taubenberger JK, Kash JC, Morens DM. The 1918 influenza pand emic: 100 years of 
questions answered and unanswered. Sci Transl Med. 2019;11(502).  
3. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, et al. Estimated 
global mortality associate d with the first 12 months of 2009 pandemic influenza A H1N1 virus 
circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687 -95. 
4. Eckroade RJ, Silverman LA, Acland HM. Avian influenz a in Pennsylvania. In: 
Proceedings of West Poultry Disease Conference. Davis: University of California, 1984. p. 1 -2. 
5. García M, Crawford JM, Latimer JW, Rivera -Cruz E, Perdue ML. Heterogene ity in the 
haemagglutinin gene and emergence of the highly pathogenic phenotype among recent H5N2 
avian influenza viruses from Mexico. J Gen Virol. 1996;77 (Pt 7):1493 -504. 
6. Hamid S, Arima Y , Dueger E, Konings F, Bell L, Lee CK, et al. From H5N1 to HxNy: An 
epidemiologic overview of human infections with avian influenza in the Western Pacific Region, 
2003 -2017. Western Pac Surveill Response J. 2018;9(5 Suppl 1):53 -67. 
7. Ko EJ, Kang SM. Immunology and efficacy of MF59 -adjuvanted vaccines. Hum Vaccin 
Immunother. 2018;14(12):3041 -5. 
8. O'Hagan DT, Ott GS, Nest GV, Rappu oli R, Giudice GD. The history of MF59(®) 
adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013;12(1):13 -30. 
9. Black S. Safety and effectiveness of MF -59 adjuvanted influenza vaccines in children and 
adults. Vaccine. 2015;33 Suppl 2:B3 -5. 
10. Treanor JJ, Essink B, Hull S, Reed S, Izikson R, Patriarca P, et al. Evaluation of safety and 
immunogenicity of re combinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with 
and without a stable oil -in-water emulsion containing glucopyranosyl -lipid A (SE+GLA) 
adjuvant. Vaccine. 2013;31(48):5760 -5. 
11. Treanor JJ, Chu L, Essink B, Muse D, El Sahly HM, Izikson R, et al. Stable emulsion (SE) 
alone is an effective adjuvant for a recombinant, baculovirus -expressed H5 influenza vaccine in 
healthy adults: A Phase 2 trial. Vaccine. 2017;35(6):923 -8. 
12. Stadlbauer D, Rajabhathor A, Amanat F, Kaplan D, Masud A, Treanor JJ, et al. 
Vaccination with a Recombinant H7 Hemagglutinin -Based Influenza Virus Vaccine Induces 
Broadly Reactive Antibodie s in Humans. mSphere. 2017;2(6).  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 83 of 84 13. Oshansky CM, Schweinle JE, Lu D, Zhou J, Pavetto C, Biscardi K, et al. Rationally 
designed heterologous prime and boost vaccination strategy for induction of cross -protective 
immunity using stockpiled H5 influenza virus vaccines. Poster presented at: Options X for the 
Control of Influenza; 2019 Aug 28 - Sep 01; Singapore.  
14. Legrand J, Vergu E,  Flahault A. Real -time monitoring of the influenza vaccine field 
effectiveness. Vaccine. 2006;24(44 -46):6605 -11. 
15. Rüggeberg JU, Gold MS, Bayas J -M, Blum MD, Bonhoeffer J, Friedlander S, et al. 
Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of 
immunization safety data. Vaccine. 2007;25(31):5675 -84. 
16. Sejvar JJ, Kohl KS, Gidudu J, Ama to A, Bakshi N, Baxter R, et al. Guillain –Barré 
syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and 
presentation of immunization safety data. Vaccine. 2011;29(3):599 -612. 
17. Sejvar JJ, Kohl KS, Bilynsky R, Blumberg D, Cvetkovich T, Galama J, et al. Encephalitis, 
myelitis, and acute disseminated encephalomyelitis (ADEM): Case definitions and guidelines for 
collection, analysis, and presentation of immuniz ation safety data. Vaccine. 2007;25(31):5771 -92. 
18. Food and Drug Administration. Guidance for Industry: Clinical Data Needed to Support 
the Licensure of Pandemic Influenza Vaccines. May 2007 . Available at: 
https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Guidance -for-
Industry --Clinical -Data -Needed -to-Support -the-Licensure -of-Pandemic -Influenza -Vaccines.pdf.  
19. Newcombe RG. Two -sided confidence intervals for the single proportion: comparison of 
seven methods. Stat Med. 1998;17(8):857 -72. 
20. Food and Drug Administration. Collection of Race and Eth nicity Data in Clinical Trials – 
Guidance for Industry and Food and Drug Administration Staff. October 2016. [cited 2020 May 
08]. Available from: https://www.fda.gov/regulatory -information/search -fda-guidance -
documents/collection -race-and-ethnicity -data-clinical -trials.  
Sanofi  Pasteur  VAM00001  
552 – Panblok  H7 + MF59 Protocol  Version  2.0 
 
Confidential/Proprietary Information  
Page 84 of 84 12 Sponsor Signature Page   
Signature Page for VV-CLIN-0615867 v3.0
Global-Pandemic-Flu-VAM00001-protocol-v2.0
Approve & eSign
Clinical
VV-CLIN-0615867 3.0